SB 39: Cosmetic safety: vaginal suppositories.
- Session Year: 2025-2026
- House: Senate
- Latest Version Date: 2025-10-01
Current Status:
Passed
(2025-10-01: Chaptered by Secretary of State. Chapter 208, Statutes of 2025.)
Introduced
In Committee
Awaiting First Chamber Vote
Passed First Chamber
In Committee
Awaiting Second Chamber Vote
Passed Second Chamber
Enacted
Existing law, beginning on January 1, 2027, prohibits a person or entity from manufacturing, selling, delivering, holding, or offering for sale in commerce any cosmetic product that contains any of several specified intentionally added ingredients, including boric acid, except under specified circumstances.
This bill would extend that prohibition to January 1, 2035, for vaginal suppositories containing intentionally added boric acid. The bill would require, beginning on January 1, 2027, any vaginal suppository product containing boric acid to include a product label, as defined, warning consumers that the product should not be used during pregnancy and other specified conditions. The bill would also exempt a vaginal suppository product from the above-mentioned prohibitions if the product becomes regulated by the United States Food and Drug Administration.
The bill would make related findings and declarations.
This bill would incorporate additional changes to Section 108980 of the Health and Safety Code proposed by AB 60 to be operative only if this bill and AB 60 are enacted and this bill is enacted last.
This bill would declare that it is to take effect immediately as an urgency statute.
Existing law, beginning on January 1, 2027, prohibits a person or entity from manufacturing, selling, delivering, holding, or offering for sale in commerce any cosmetic product that contains any of several specified intentionally added ingredients, including boric acid, except under specified circumstances.
This bill would extend that prohibition to January 1, 2035, for vaginal suppositories containing intentionally added boric acid. The bill would require, beginning on January 1, 2027, any vaginal suppository product containing boric acid to include a product label, as defined, warning consumers that the product should not be used during pregnancy and other specified conditions. The bill would also exempt a vaginal suppository product from the above-mentioned prohibitions if the product becomes regulated by the United States Food and Drug Administration.
The bill would make related findings and declarations.
This bill would incorporate additional changes to Section 108980 of the Health and Safety Code proposed by AB 60 to be operative only if this bill and AB 60 are enacted and this bill is enacted last.
This bill would declare that it is to take effect immediately as an urgency statute.
Existing law, beginning on January 1, 2027, prohibits a person or entity from manufacturing, selling, delivering, holding, or offering for sale in commerce any cosmetic product that contains any of several specified intentionally added ingredients, including boric acid, except under specified circumstances.
This bill would extend that prohibition to January 1, 2035, for vaginal suppositories containing intentionally added boric acid. The bill would require, beginning on January 1, 2027, any vaginal suppository product containing boric acid to include a product label, as defined, warning consumers that the product should not be used during pregnancy and other specified conditions. The bill would also exempt a vaginal suppository product from the above-mentioned prohibitions if the product becomes regulated by the United States Food and Drug Administration.
The bill would make related findings and declarations.
This bill would incorporate additional changes to Section 108980 of the Health and Safety Code proposed by AB 60 to be operative only if this bill and AB 60 are enacted and this bill is enacted last.
This bill would declare that it is to take effect immediately as an urgency statute.
Existing law law, beginning on January 1, 2027, prohibits a person or entity from manufacturing, selling, delivering, holding, or offering for sale in commerce any cosmetic product that contains any of several specified intentionally added ingredients, including boric acid, except under specified circumstances.
This bill would exempt vaginal suppositories from the prohibition on boric acid described above if specified conditions are met, including that a product has passed definitive third-party placebo-controlled double-blind safety trials. extend that prohibition to January 1, 2035, for vaginal suppositories containing intentionally added boric acid. The bill would require, beginning on January 1, 2027, any vaginal suppository product containing boric acid to include a product label, as defined, warning consumers that the product should not be used during pregnancy and other specified conditions. The bill would also exempt a vaginal suppository product from the above-mentioned prohibitions if the product becomes regulated by the United States Food and Drug Administration.
The bill would make related findings and declarations.
This bill would declare that it is to take effect immediately as an urgency statute.
Existing law prohibits a person or entity from manufacturing, selling, delivering, holding, or offering for sale in commerce any cosmetic product that contains any of several specified intentionally added ingredients ingredients, including boric acid, except under specified circumstances.
This bill would exempt vaginal or vulvar products from the prohibitions suppositories from the prohibition on boric acid described above if specified conditions are met, including that a product has passed definitive third-party placebo-controlled double-blind safety trials.
The bill would make related findings and declarations.
This bill would declare that it is to take effect immediately as an urgency statute.
Existing law prohibits a person or entity from manufacturing, selling, delivering, holding, or offering for sale in commerce any cosmetic product that contains any of several specified intentionally added ingredients except under specified circumstances.
This bill would exempt vaginal or vulvar products from the prohibitions described above if specified conditions are met, including that a product has passed definitive third-party placebo-controlled double-blind safety trials.
The bill would make related findings and declarations.
This bill would declare that it is to take effect immediately as an urgency statute.
Existing law prohibits a person or entity from manufacturing, selling, delivering, holding, or offering for sale in commerce any cosmetic product that contains any of several specified intentionally added ingredients except under specified circumstances.
This bill would exempt vaginal or vulvar products from the prohibitions described above if specified conditions are met, including that a product has passed definitive third-party placebo-controlled double-blind safety trials.
The bill would make related findings and declarations.
The Legislature finds and declares all of the following:
(a)According to published research from Johns Hopkins University, intravaginal boric acid represents one of the few available options for addressing recurrent vaginal yeast and bacterial infections, including infections caused by azole-resistant Candida and nitroimidazole-resistant Trichomoniasis. Intravaginal boric acid is included in multiple national guidelines for addressing infectious vaginitis, including guidelines issued by the American College of Obstetricians and Gynecologists and the federal Centers for Disease Control and Prevention.
(b)Research suggests that intravaginal boric acid is well tolerated for use in addressing recurrent vaginal infections. However, little is known about the safety of intravaginal boric acid use during pregnancy, and animal studies show that high levels of oral exposure are associated with increased risk of birth defects. As a result, guidelines issued by the American College of Obstetricians and Gynecologists and health care professional associations in other countries, including Canada and the United Kingdom, recommend against intravaginal boric acid use during pregnancy, or recommend that persons use reliable contraception while using intravaginal boric acid.
(c)Existing state law bans, beginning January 1, 2027, the manufacture and sale of any cosmetic product containing specified chemicals as intentionally added ingredients, including boric acid. Because the use of intravaginal boric acid represents one of the few available options for addressing recurrent vaginal infections, additional time for vaginal suppository products containing intentionally added boric acid is warranted to allow these products time to become regulated as a drug under the United States Food and Drug Administration.
SEC. 2.Section 108980 of the Health and Safety Code is amended to read:108980.(a)Commencing January 1, 2025, no person or entity shall manufacture, sell, deliver, hold, or offer for sale in commerce any cosmetic product that contains any of the following intentionally added ingredients:
(1)Dibutyl phthalate (CAS no. 84-74-2).
(2)Diethylhexyl phthalate (CAS no. 117-81-7).
(3)Formaldehyde (CAS no. 50-00-0).
(4)Paraformaldehyde (CAS no. 30525-89-4).
(5)Methylene glycol (CAS no. 463-57-0).
(6)Quaternium-15 (CAS no. 51229-78-8).
(7)Mercury (CAS no. 7439-97-6).
(8)Isobutylparaben (CAS no. 4247-02-3).
(9)Isopropylparaben (CAS no. 4191-73-5).
(10)m-Phenylenediamine and its salts (CAS no. 108-45-2).
(11)o-Phenylenediamine and its salts (CAS no. 95-54-5).
(12)The following per- and polyfluoroalkyl substances (PFAS) and their salts:
(A)Perfluorooctane sulfonate (PFOS); heptadecafluorooctane-1-sulfonic acid (CAS no. 1763-23-1).
(B)Potassium perfluorooctanesulfonate; potassium heptadecafluorooctane-1-sulfonate (CAS no. 2795-39-3).
(C)Diethanolamine perfluorooctane sulfonate (CAS 70225-14-8).
(D)Ammonium perfluorooctane sulfonate; ammonium heptadecafluorooctanesulfonate (CAS 29081-56-9).
(E)Lithium perfluorooctane sulfonate; lithium heptadecafluorooctanesulfonate (CAS 29457-72-5).
(F)Perfluorooctanoic acid (PFOA)(CAS no. 335-67-1).
(G)Ammonium pentadecafluorooctanoate (CAS no. 3825-26-1).
(H)Nonadecafluorodecanoic acid (CAS no. 355-76-2).
(I)Ammonium nonadecafluorodecanoate (CAS no. 3108-42-7).
(J)Sodium nonadecafluorodecanoate (CAS no. 3830-45-3).
(K)Perfluorononanoic acid (PFNA)(CAS no. 375-95-1).
(L)Sodium heptadecafluorononanoate (CAS no. 21049-39-8).
(M)Ammonium perfluorononanoate (CAS no. 4149-60-4).
(b)Except as provided in paragraph (2) of subdivision (e), commencing January 1, 2027, no person or entity shall manufacture, sell, deliver, hold, or offer for sale in commerce any cosmetic product that contains any of the following intentionally added ingredients:
(1)Lily aldehyde (CAS no. 80-54-6).
(2)Acetaldehyde (CAS no. 75-07-0).
(3)Cyclohexylamine (CAS no. 108-91-8).
(4)Cyclotetrasiloxane (CAS no. 556-67-2).
(5)Phytonadione (CAS no. 84-80-0).
(6)Sodium perborate (CAS no. 15120-21-5).
(7)Styrene (CAS no. 100-42-5).
(8)Trichloroacetic acid (CAS no. 76-03-9).
(9)Tricresyl phosphate (CAS no. 1330-78-5).
(10)Vinyl acetate (CAS no. 108-05-4).
(11)2-Chloracetamide (CAS no. 79-07-2).
(12)Allyl isothiocyanate (CAS no. 57-06-7).
(13)Anthraquinone (CAS no. 84-65-1).
(14)Malachite green (CAS no. 569-64-2).
(15)Oil from the seeds of Laurus nobilis L. (CAS no. 84603-73-6).
(16)Pyrogallol (CAS no. 87-66-1).
(17)C.I. disperse blue 1 (CAS no. 2475-45-8).
(18)Trisodium nitrilotriacetate (CAS no. 5064-31-3).
(19)The following boron substances:
(A)Perboric acids:
(i)Sodium salt (CAS no. 11138-47-9).
(ii)Sodium salt, monohydrate (CAS no. 12040-72-1).
(iii)Sodium perborate monohydrate (CAS no. 10332-33-9).
(B)Boric acid (CAS nos. 10043-35-3 and 11113-50-1).
(C)Borates, tetraborates, octaborates, and boric acid salts and esters, including all of the following:
(i)Disodium octaborate anhydrous (CAS no. 12008-41-2).
(ii)Disodium octaborate tetrahydrate (CAS no. 12280-03-4).
(iii)2-Aminoethanol, monoester with boric acid (CAS no. 10377-81-8).
(iv)2-Hydroxypropyl ammonium dihydrogen orthoborate (CAS no. 68003-13-4).
(v)Potassium borate, boric acid potassium salt (CAS no. 12712-38-8).
(vi)Trioctyldodecyl borate.
(vii)Zinc borate (CAS no. 1332-07-6).
(viii)Sodium borate, disodium tetraborate anhydrous; boric acid, sodium salt (CAS no. 1330-43-4).
(ix)Tetraboron disodium heptaoxide, hydrate (CAS no. 12267-73-1).
(x)Orthoboric acid, sodium salt (CAS no. 13840-56-7).
(xi)Disodium tetraborate decahydrate; borax decahydrate (CAS no. 1303-96-4).
(xii)Disodium tetraborate pentahydrate; borax pentahydrate (CAS no. 12179-04-3).
(20)C.I. disperse blue 3 (CAS no. 2475-46-9).
(21)Basic green 1 (CAS no. 633-03-4).
(22)Basic blue 7 (CAS no. 2390-60-5).
(23)3(or5)-((4-(benzylmethylamino)phenyl)azo)-1,2 -(or1,4)-dimethyl-1H-1,2,4-triazolium and its salts (CAS nos. 89959-98-8 and 12221-69-1).
(24)Basic violet 4 (CAS no. 2390-59-2).
(25)Basic blue 3 (CAS no. 33203-82-6).
(26)Basic blue 9 (CAS no. 61-73-4).
(c)If a cosmetic product made through manufacturing processes intended to comply with this chapter contains a technically unavoidable trace quantity of an ingredient listed in subdivision (a) or (b) and that trace quantity stems from impurities of natural or synthetic ingredients, the manufacturing process, storage, or migration from packaging, that trace quantity shall not cause the cosmetic product to be in violation of this section.
(d)For purposes of this section, ingredient has the same meaning as defined in Section 111791.5.
(e)(1)Commencing January 1, 2027, a person or entity that manufactures, sells, delivers, holds, or offers for sale in commerce a vaginal suppository product containing intentionally added boric acid (CAS nos. 10043-35-3 and 11113-50-1) shall include on the product label the following statement: WARNING: IT IS RECOMMENDED TO CONSULT WITH A DOCTOR BEFORE USE, particularly if you have sensitivity in your lower pelvis or abdomen, a sexually transmitted disease (STD), pelvic inflammatory disease (PID), vaginal bleeding, sores, ulcerations, nausea, fever, or chills. Do not use on broken or irritated skin. Stop use and contact a doctor if symptoms persist or worsen, or if you experience irritation, burning, bleeding, or cramping. NOT FOR ORAL CONSUMPTION. FOR VAGINAL USE ONLY. DO NOT USE IF PREGNANT, TRYING TO CONCEIVE, OR NURSING. IF YOU BECOME PREGNANT WHILE USING THIS PRODUCT, DISCONTINUE USE IMMEDIATELY. If swallowed, get medical help or contact Poison Control Center immediately. Some boric acid suppository products may break down a condomensure product has completely dissolved before having sex.
(2)Commencing January 1, 2035, no person or entity shall manufacture, sell, deliver, hold, or offer for sale in commerce a vaginal suppository product that contains intentionally added boric acid (CAS nos. 10043-35-3 and 11113-50-1).
(3)Paragraphs (1) and (2) shall not apply to a vaginal suppository product containing intentionally added boric acid (CAS nos. 10043-35-3 and 11113-50-1) if the product becomes regulated as a drug by the United States Food and Drug Administration.
SEC. 2.5.Section 108980 of the Health and Safety Code is amended to read:108980.(a)Commencing January 1, 2025, a person or entity shall not manufacture, sell, deliver, hold, or offer for sale in commerce any cosmetic product that contains any of the following intentionally added ingredients:
(1)Dibutyl phthalate (CAS no. 84-74-2).
(2)Diethylhexyl phthalate (CAS no. 117-81-7).
(3)Formaldehyde (CAS no. 50-00-0).
(4)Paraformaldehyde (CAS no. 30525-89-4).
(5)Methylene glycol (CAS no. 463-57-0).
(6)Quaternium-15 (CAS no. 51229-78-8).
(7)Mercury (CAS no. 7439-97-6).
(8)Isobutylparaben (CAS no. 4247-02-3).
(9)Isopropylparaben (CAS no. 4191-73-5).
(10)m-Phenylenediamine and its salts (CAS no. 108-45-2).
(11)o-Phenylenediamine and its salts (CAS no. 95-54-5).
(12)The following per- and polyfluoroalkyl substances (PFAS) and their salts:
(A)Perfluorooctane sulfonate (PFOS); heptadecafluorooctane-1-sulfonic acid (CAS no. 1763-23-1).
(B)Potassium perfluorooctanesulfonate; potassium heptadecafluorooctane-1-sulfonate (CAS no. 2795-39-3).
(C)Diethanolamine perfluorooctane sulfonate (CAS 70225-14-8).
(D)Ammonium perfluorooctane sulfonate; ammonium heptadecafluorooctanesulfonate (CAS 29081-56-9).
(E)Lithium perfluorooctane sulfonate; lithium heptadecafluorooctanesulfonate (CAS 29457-72-5).
(F)Perfluorooctanoic acid (PFOA)(CAS no. 335-67-1).
(G)Ammonium pentadecafluorooctanoate (CAS no. 3825-26-1).
(H)Nonadecafluorodecanoic acid (CAS no. 355-76-2).
(I)Ammonium nonadecafluorodecanoate (CAS no. 3108-42-7).
(J)Sodium nonadecafluorodecanoate (CAS no. 3830-45-3).
(K)Perfluorononanoic acid (PFNA)(CAS no. 375-95-1).
(L)Sodium heptadecafluorononanoate (CAS no. 21049-39-8).
(M)Ammonium perfluorononanoate (CAS no. 4149-60-4).
(b)Except as provided in paragraph (2) of subdivision (f), commencing January 1, 2027, no person or entity shall manufacture, sell, deliver, hold, or offer for sale in commerce any cosmetic product that contains any of the following intentionally added ingredients:
(1)Lily aldehyde (CAS no. 80-54-6).
(2)Acetaldehyde (CAS no. 75-07-0).
(3)Cyclohexylamine (CAS no. 108-91-8).
(4)Cyclotetrasiloxane (CAS no. 556-67-2).
(5)Phytonadione (CAS no. 84-80-0).
(6)Sodium perborate (CAS no. 15120-21-5).
(7)Styrene (CAS no. 100-42-5).
(8)Trichloroacetic acid (CAS no. 76-03-9).
(9)Tricresyl phosphate (CAS no. 1330-78-5).
(10)Vinyl acetate (CAS no. 108-05-4).
(11)2-Chloracetamide (CAS no. 79-07-2).
(12)Allyl isothiocyanate (CAS no. 57-06-7).
(13)Anthraquinone (CAS no. 84-65-1).
(14)Malachite green (CAS no. 569-64-2).
(15)Oil from the seeds of Laurus nobilis L. (CAS no. 84603-73-6).
(16)Pyrogallol (CAS no. 87-66-1).
(17)C.I. disperse blue 1 (CAS no. 2475-45-8).
(18)Trisodium nitrilotriacetate (CAS no. 5064-31-3).
(19)The following boron substances:
(A)Perboric acids:
(i)Sodium salt (CAS no. 11138-47-9).
(ii)Sodium salt, monohydrate (CAS no. 12040-72-1).
(iii)Sodium perborate monohydrate (CAS no. 10332-33-9).
(B)Boric acid (CAS nos. 10043-35-3 and 11113-50-1).
(C)Borates, tetraborates, octaborates, and boric acid salts and esters, including all of the following:
(i)Disodium octaborate anhydrous (CAS no. 12008-41-2).
(ii)Disodium octaborate tetrahydrate (CAS no. 12280-03-4).
(iii)2-Aminoethanol, monoester with boric acid (CAS no. 10377-81-8).
(iv)2-Hydroxypropyl ammonium dihydrogen orthoborate (CAS no. 68003-13-4).
(v)Potassium borate, boric acid potassium salt (CAS no. 12712-38-8).
(vi)Trioctyldodecyl borate.
(vii)Zinc borate (CAS no. 1332-07-6).
(viii)Sodium borate, disodium tetraborate anhydrous; boric acid, sodium salt (CAS no. 1330-43-4).
(ix)Tetraboron disodium heptaoxide, hydrate (CAS no. 12267-73-1).
(x)Orthoboric acid, sodium salt (CAS no. 13840-56-7).
(xi)Disodium tetraborate decahydrate; borax decahydrate (CAS no. 1303-96-4).
(xii)Disodium tetraborate pentahydrate; borax pentahydrate (CAS no. 12179-04-3).
(20)C.I. disperse blue 3 (CAS no. 2475-46-9).
(21)Basic green 1 (CAS no. 633-03-4).
(22)Basic blue 7 (CAS no. 2390-60-5).
(23)3(or5)-((4-(benzylmethylamino)phenyl)azo)-1,2 -(or1,4)-dimethyl-1H-1,2,4-triazolium and its salts (CAS nos. 89959-98-8 and 12221-69-1).
(24)Basic violet 4 (CAS no. 2390-59-2).
(25)Basic blue 3 (CAS no. 33203-82-6).
(26)Basic blue 9 (CAS no. 61-73-4).
(27)Musk ambrette (CAS no. 83-66-9).
(28)Musk tibetene (CAS no.145-39-1).
(29)Musk moskene (CAS no. 116-66-5).
(30)Musk xylene (CAS no. 81-15-2).
(c)(1)Commencing January 1, 2027, a person or entity shall not manufacture, sell, deliver, hold, or offer for sale in commerce a cosmetic product that contains more than 1.4 percent in fine fragrance products, 0.56 percent in eau de toilette, 0 percent in oral products, and 0.042 percent in all other products of musk ketone (CAS no. 81-14-1).
(2)Oral products means a cosmetic product that is intended to be applied on teeth or the mucous membranes of the oral cavity.
(d)If a cosmetic product made through manufacturing processes intended to comply with this chapter contains a technically unavoidable trace quantity of an ingredient listed in subdivision (a) or (b) and that trace quantity stems from impurities of natural or synthetic ingredients, the manufacturing process, storage, or migration from packaging, that trace quantity shall not cause the cosmetic product to be in violation of this section.
(e)For purposes of this section, ingredient has the same meaning as defined in Section 111791.5.
(f)(1)Commencing January 1, 2027, a person or entity that manufactures, sells, delivers, holds, or offers for sale in commerce a vaginal suppository product containing intentionally added boric acid (CAS nos. 10043-35-3 and 11113-50-1) shall include on the product label the following statement: WARNING: IT IS RECOMMENDED TO CONSULT WITH A DOCTOR BEFORE USE, particularly if you have sensitivity in your lower pelvis or abdomen, a sexually transmitted disease (STD), pelvic inflammatory disease (PID), vaginal bleeding, sores, ulcerations, nausea, fever, or chills. Do not use on broken or irritated skin. Stop use and contact a doctor if symptoms persist or worsen, or if you experience irritation, burning, bleeding, or cramping. NOT FOR ORAL CONSUMPTION. FOR VAGINAL USE ONLY. DO NOT USE IF PREGNANT, TRYING TO CONCEIVE, OR NURSING. IF YOU BECOME PREGNANT WHILE USING THIS PRODUCT, DISCONTINUE USE IMMEDIATELY. If swallowed, get medical help or contact Poison Control Center immediately. Some boric acid suppository products may break down a condomensure product has completely dissolved before having sex.
(2)Commencing January 1, 2035, no person or entity shall manufacture, sell, deliver, hold, or offer for sale in commerce a vaginal suppository product that contains intentionally added boric acid (CAS nos. 10043-35-3 and 11113-50-1).
(3)Paragraphs (1) and (2) shall not apply to a vaginal suppository product containing intentionally added boric acid (CAS nos. 10043-35-3 and 11113-50-1) if the product becomes regulated as a drug by the United States Food and Drug Administration.
SEC. 3.Section 108982 of the Health and Safety Code is amended to read:108982.For purposes of this chapter, the following terms have the following definitions:
(a)Cosmetic product means an article for retail sale or professional use intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to the human body for cleansing, beautifying, promoting attractiveness, or altering the appearance.
(b)Perfluoroalkyl and polyfluoroalkyl substances or PFAS means a class of fluorinated organic chemicals containing at least one fully fluorinated carbon atom.
(c)Intentionally added PFAS means either of the following:
(1)PFAS chemicals that a manufacturer has intentionally added to a product and that have a functional or technical effect on the product.
(2)PFAS chemicals that are intentional breakdown products of an added chemical.
(d)Product label means a display of written, printed, or graphic matter upon a cosmetic product or upon its immediate container.
SEC. 4.Section 2.5 of this bill incorporates amendments to Section 108980 of the Health and Safety Code proposed by both this bill and Assembly Bill 60. That section of this bill shall only become operative if (1) both bills are enacted and become effective on or before January 1, 2026, but this bill becomes operative first, (2) each bill amends Section 108980 of the Health and Safety Code, and (3) this bill is enacted after Assembly Bill 60, in which case Section 108980 of the Health and Safety Code, as amended by Section 2 of this bill, shall remain operative only until the operative date of Assembly Bill 60, at which time Section 2.5 of this bill shall become operative.
SEC. 5.This act is an urgency statute necessary for the immediate preservation of the public peace, health, or safety within the meaning of Article IV of the California Constitution and shall go into immediate effect. The facts constituting the necessity are:
In order for women in this state to have necessary medical and hygiene materials available to them in a timely manner, it is necessary that this act take effect immediately.
The Legislature finds and declares all of the following:
(a)According to published research from Johns Hopkins University, intravaginal boric acid represents one of the few available options for addressing recurrent vaginal yeast and bacterial infections, including infections caused by azole-resistant Candida and nitroimidazole-resistant Trichomoniasis. Intravaginal boric acid is included in multiple national guidelines for addressing infectious vaginitis, including guidelines issued by the American College of Obstetricians and Gynecologists and the federal Centers for Disease Control and Prevention.
(b)Research suggests that intravaginal boric acid is well tolerated for use in addressing recurrent vaginal infections. However, little is known about the safety of intravaginal boric acid use during pregnancy, and animal studies show that high levels of oral exposure are associated with increased risk of birth defects. As a result, guidelines issued by the American College of Obstetricians and Gynecologists and health care professional associations in other countries, including Canada and the United Kingdom, recommend against intravaginal boric acid use during pregnancy, or recommend that persons use reliable contraception while using intravaginal boric acid.
(c)Existing state law bans, beginning January 1, 2027, the manufacture and sale of any cosmetic product containing specified chemicals as intentionally added ingredients, including boric acid. Because the use of intravaginal boric acid represents one of the few available options for addressing recurrent vaginal infections, additional time for vaginal suppository products containing intentionally added boric acid is warranted to allow these products time to become regulated as a drug under the United States Food and Drug Administration.
SEC. 2.Section 108980 of the Health and Safety Code is amended to read:108980.(a)Commencing January 1, 2025, no person or entity shall manufacture, sell, deliver, hold, or offer for sale in commerce any cosmetic product that contains any of the following intentionally added ingredients:
(1)Dibutyl phthalate (CAS no. 84-74-2).
(2)Diethylhexyl phthalate (CAS no. 117-81-7).
(3)Formaldehyde (CAS no. 50-00-0).
(4)Paraformaldehyde (CAS no. 30525-89-4).
(5)Methylene glycol (CAS no. 463-57-0).
(6)Quaternium-15 (CAS no. 51229-78-8).
(7)Mercury (CAS no. 7439-97-6).
(8)Isobutylparaben (CAS no. 4247-02-3).
(9)Isopropylparaben (CAS no. 4191-73-5).
(10)m-Phenylenediamine and its salts (CAS no. 108-45-2).
(11)o-Phenylenediamine and its salts (CAS no. 95-54-5).
(12)The following per- and polyfluoroalkyl substances (PFAS) and their salts:
(A)Perfluorooctane sulfonate (PFOS); heptadecafluorooctane-1-sulfonic acid (CAS no. 1763-23-1).
(B)Potassium perfluorooctanesulfonate; potassium heptadecafluorooctane-1-sulfonate (CAS no. 2795-39-3).
(C)Diethanolamine perfluorooctane sulfonate (CAS 70225-14-8).
(D)Ammonium perfluorooctane sulfonate; ammonium heptadecafluorooctanesulfonate (CAS 29081-56-9).
(E)Lithium perfluorooctane sulfonate; lithium heptadecafluorooctanesulfonate (CAS 29457-72-5).
(F)Perfluorooctanoic acid (PFOA)(CAS no. 335-67-1).
(G)Ammonium pentadecafluorooctanoate (CAS no. 3825-26-1).
(H)Nonadecafluorodecanoic acid (CAS no. 355-76-2).
(I)Ammonium nonadecafluorodecanoate (CAS no. 3108-42-7).
(J)Sodium nonadecafluorodecanoate (CAS no. 3830-45-3).
(K)Perfluorononanoic acid (PFNA)(CAS no. 375-95-1).
(L)Sodium heptadecafluorononanoate (CAS no. 21049-39-8).
(M)Ammonium perfluorononanoate (CAS no. 4149-60-4).
(b)Except as provided in paragraph (2) of subdivision (e), commencing January 1, 2027, no person or entity shall manufacture, sell, deliver, hold, or offer for sale in commerce any cosmetic product that contains any of the following intentionally added ingredients:
(1)Lily aldehyde (CAS no. 80-54-6).
(2)Acetaldehyde (CAS no. 75-07-0).
(3)Cyclohexylamine (CAS no. 108-91-8).
(4)Cyclotetrasiloxane (CAS no. 556-67-2).
(5)Phytonadione (CAS no. 84-80-0).
(6)Sodium perborate (CAS no. 15120-21-5).
(7)Styrene (CAS no. 100-42-5).
(8)Trichloroacetic acid (CAS no. 76-03-9).
(9)Tricresyl phosphate (CAS no. 1330-78-5).
(10)Vinyl acetate (CAS no. 108-05-4).
(11)2-Chloracetamide (CAS no. 79-07-2).
(12)Allyl isothiocyanate (CAS no. 57-06-7).
(13)Anthraquinone (CAS no. 84-65-1).
(14)Malachite green (CAS no. 569-64-2).
(15)Oil from the seeds of Laurus nobilis L. (CAS no. 84603-73-6).
(16)Pyrogallol (CAS no. 87-66-1).
(17)C.I. disperse blue 1 (CAS no. 2475-45-8).
(18)Trisodium nitrilotriacetate (CAS no. 5064-31-3).
(19)The following boron substances:
(A)Perboric acids:
(i)Sodium salt (CAS no. 11138-47-9).
(ii)Sodium salt, monohydrate (CAS no. 12040-72-1).
(iii)Sodium perborate monohydrate (CAS no. 10332-33-9).
(B)Boric acid (CAS nos. 10043-35-3 and 11113-50-1).
(C)Borates, tetraborates, octaborates, and boric acid salts and esters, including all of the following:
(i)Disodium octaborate anhydrous (CAS no. 12008-41-2).
(ii)Disodium octaborate tetrahydrate (CAS no. 12280-03-4).
(iii)2-Aminoethanol, monoester with boric acid (CAS no. 10377-81-8).
(iv)2-Hydroxypropyl ammonium dihydrogen orthoborate (CAS no. 68003-13-4).
(v)Potassium borate, boric acid potassium salt (CAS no. 12712-38-8).
(vi)Trioctyldodecyl borate.
(vii)Zinc borate (CAS no. 1332-07-6).
(viii)Sodium borate, disodium tetraborate anhydrous; boric acid, sodium salt (CAS no. 1330-43-4).
(ix)Tetraboron disodium heptaoxide, hydrate (CAS no. 12267-73-1).
(x)Orthoboric acid, sodium salt (CAS no. 13840-56-7).
(xi)Disodium tetraborate decahydrate; borax decahydrate (CAS no. 1303-96-4).
(xii)Disodium tetraborate pentahydrate; borax pentahydrate (CAS no. 12179-04-3).
(20)C.I. disperse blue 3 (CAS no. 2475-46-9).
(21)Basic green 1 (CAS no. 633-03-4).
(22)Basic blue 7 (CAS no. 2390-60-5).
(23)3(or5)-((4-(benzylmethylamino)phenyl)azo)-1,2 -(or1,4)-dimethyl-1H-1,2,4-triazolium and its salts (CAS nos. 89959-98-8 and 12221-69-1).
(24)Basic violet 4 (CAS no. 2390-59-2).
(25)Basic blue 3 (CAS no. 33203-82-6).
(26)Basic blue 9 (CAS no. 61-73-4).
(c)If a cosmetic product made through manufacturing processes intended to comply with this chapter contains a technically unavoidable trace quantity of an ingredient listed in subdivision (a) or (b) and that trace quantity stems from impurities of natural or synthetic ingredients, the manufacturing process, storage, or migration from packaging, that trace quantity shall not cause the cosmetic product to be in violation of this section.
(d)For purposes of this section, ingredient has the same meaning as defined in Section 111791.5.
(e)(1)Commencing January 1, 2027, a person or entity that manufactures, sells, delivers, holds, or offers for sale in commerce a vaginal suppository product containing intentionally added boric acid (CAS nos. 10043-35-3 and 11113-50-1) shall include on the product label the following statement: WARNING: IT IS RECOMMENDED TO CONSULT WITH A DOCTOR BEFORE USE, particularly if you have sensitivity in your lower pelvis or abdomen, a sexually transmitted disease (STD), pelvic inflammatory disease (PID), vaginal bleeding, sores, ulcerations, nausea, fever, or chills. Do not use on broken or irritated skin. Stop use and contact a doctor if symptoms persist or worsen, or if you experience irritation, burning, bleeding, or cramping. NOT FOR ORAL CONSUMPTION. FOR VAGINAL USE ONLY. DO NOT USE IF PREGNANT, TRYING TO CONCEIVE, OR NURSING. IF YOU BECOME PREGNANT WHILE USING THIS PRODUCT, DISCONTINUE USE IMMEDIATELY. If swallowed, get medical help or contact Poison Control Center immediately. Some boric acid suppository products may break down a condomensure product has completely dissolved before having sex.
(2)Commencing January 1, 2035, no person or entity shall manufacture, sell, deliver, hold, or offer for sale in commerce a vaginal suppository product that contains intentionally added boric acid (CAS nos. 10043-35-3 and 11113-50-1).
(3)Paragraphs (1) and (2) shall not apply to a vaginal suppository product containing intentionally added boric acid (CAS nos. 10043-35-3 and 11113-50-1) if the product becomes regulated as a drug by the United States Food and Drug Administration.
SEC. 2.5.Section 108980 of the Health and Safety Code is amended to read:108980.(a)Commencing January 1, 2025, a person or entity shall not manufacture, sell, deliver, hold, or offer for sale in commerce any cosmetic product that contains any of the following intentionally added ingredients:
(1)Dibutyl phthalate (CAS no. 84-74-2).
(2)Diethylhexyl phthalate (CAS no. 117-81-7).
(3)Formaldehyde (CAS no. 50-00-0).
(4)Paraformaldehyde (CAS no. 30525-89-4).
(5)Methylene glycol (CAS no. 463-57-0).
(6)Quaternium-15 (CAS no. 51229-78-8).
(7)Mercury (CAS no. 7439-97-6).
(8)Isobutylparaben (CAS no. 4247-02-3).
(9)Isopropylparaben (CAS no. 4191-73-5).
(10)m-Phenylenediamine and its salts (CAS no. 108-45-2).
(11)o-Phenylenediamine and its salts (CAS no. 95-54-5).
(12)The following per- and polyfluoroalkyl substances (PFAS) and their salts:
(A)Perfluorooctane sulfonate (PFOS); heptadecafluorooctane-1-sulfonic acid (CAS no. 1763-23-1).
(B)Potassium perfluorooctanesulfonate; potassium heptadecafluorooctane-1-sulfonate (CAS no. 2795-39-3).
(C)Diethanolamine perfluorooctane sulfonate (CAS 70225-14-8).
(D)Ammonium perfluorooctane sulfonate; ammonium heptadecafluorooctanesulfonate (CAS 29081-56-9).
(E)Lithium perfluorooctane sulfonate; lithium heptadecafluorooctanesulfonate (CAS 29457-72-5).
(F)Perfluorooctanoic acid (PFOA)(CAS no. 335-67-1).
(G)Ammonium pentadecafluorooctanoate (CAS no. 3825-26-1).
(H)Nonadecafluorodecanoic acid (CAS no. 355-76-2).
(I)Ammonium nonadecafluorodecanoate (CAS no. 3108-42-7).
(J)Sodium nonadecafluorodecanoate (CAS no. 3830-45-3).
(K)Perfluorononanoic acid (PFNA)(CAS no. 375-95-1).
(L)Sodium heptadecafluorononanoate (CAS no. 21049-39-8).
(M)Ammonium perfluorononanoate (CAS no. 4149-60-4).
(b)Except as provided in paragraph (2) of subdivision (f), commencing January 1, 2027, no person or entity shall manufacture, sell, deliver, hold, or offer for sale in commerce any cosmetic product that contains any of the following intentionally added ingredients:
(1)Lily aldehyde (CAS no. 80-54-6).
(2)Acetaldehyde (CAS no. 75-07-0).
(3)Cyclohexylamine (CAS no. 108-91-8).
(4)Cyclotetrasiloxane (CAS no. 556-67-2).
(5)Phytonadione (CAS no. 84-80-0).
(6)Sodium perborate (CAS no. 15120-21-5).
(7)Styrene (CAS no. 100-42-5).
(8)Trichloroacetic acid (CAS no. 76-03-9).
(9)Tricresyl phosphate (CAS no. 1330-78-5).
(10)Vinyl acetate (CAS no. 108-05-4).
(11)2-Chloracetamide (CAS no. 79-07-2).
(12)Allyl isothiocyanate (CAS no. 57-06-7).
(13)Anthraquinone (CAS no. 84-65-1).
(14)Malachite green (CAS no. 569-64-2).
(15)Oil from the seeds of Laurus nobilis L. (CAS no. 84603-73-6).
(16)Pyrogallol (CAS no. 87-66-1).
(17)C.I. disperse blue 1 (CAS no. 2475-45-8).
(18)Trisodium nitrilotriacetate (CAS no. 5064-31-3).
(19)The following boron substances:
(A)Perboric acids:
(i)Sodium salt (CAS no. 11138-47-9).
(ii)Sodium salt, monohydrate (CAS no. 12040-72-1).
(iii)Sodium perborate monohydrate (CAS no. 10332-33-9).
(B)Boric acid (CAS nos. 10043-35-3 and 11113-50-1).
(C)Borates, tetraborates, octaborates, and boric acid salts and esters, including all of the following:
(i)Disodium octaborate anhydrous (CAS no. 12008-41-2).
(ii)Disodium octaborate tetrahydrate (CAS no. 12280-03-4).
(iii)2-Aminoethanol, monoester with boric acid (CAS no. 10377-81-8).
(iv)2-Hydroxypropyl ammonium dihydrogen orthoborate (CAS no. 68003-13-4).
(v)Potassium borate, boric acid potassium salt (CAS no. 12712-38-8).
(vi)Trioctyldodecyl borate.
(vii)Zinc borate (CAS no. 1332-07-6).
(viii)Sodium borate, disodium tetraborate anhydrous; boric acid, sodium salt (CAS no. 1330-43-4).
(ix)Tetraboron disodium heptaoxide, hydrate (CAS no. 12267-73-1).
(x)Orthoboric acid, sodium salt (CAS no. 13840-56-7).
(xi)Disodium tetraborate decahydrate; borax decahydrate (CAS no. 1303-96-4).
(xii)Disodium tetraborate pentahydrate; borax pentahydrate (CAS no. 12179-04-3).
(20)C.I. disperse blue 3 (CAS no. 2475-46-9).
(21)Basic green 1 (CAS no. 633-03-4).
(22)Basic blue 7 (CAS no. 2390-60-5).
(23)3(or5)-((4-(benzylmethylamino)phenyl)azo)-1,2 -(or1,4)-dimethyl-1H-1,2,4-triazolium and its salts (CAS nos. 89959-98-8 and 12221-69-1).
(24)Basic violet 4 (CAS no. 2390-59-2).
(25)Basic blue 3 (CAS no. 33203-82-6).
(26)Basic blue 9 (CAS no. 61-73-4).
(27)Musk ambrette (CAS no. 83-66-9).
(28)Musk tibetene (CAS no.145-39-1).
(29)Musk moskene (CAS no. 116-66-5).
(30)Musk xylene (CAS no. 81-15-2).
(c)(1)Commencing January 1, 2027, a person or entity shall not manufacture, sell, deliver, hold, or offer for sale in commerce a cosmetic product that contains more than 1.4 percent in fine fragrance products, 0.56 percent in eau de toilette, 0 percent in oral products, and 0.042 percent in all other products of musk ketone (CAS no. 81-14-1).
(2)Oral products means a cosmetic product that is intended to be applied on teeth or the mucous membranes of the oral cavity.
(d)If a cosmetic product made through manufacturing processes intended to comply with this chapter contains a technically unavoidable trace quantity of an ingredient listed in subdivision (a) or (b) and that trace quantity stems from impurities of natural or synthetic ingredients, the manufacturing process, storage, or migration from packaging, that trace quantity shall not cause the cosmetic product to be in violation of this section.
(e)For purposes of this section, ingredient has the same meaning as defined in Section 111791.5.
(f)(1)Commencing January 1, 2027, a person or entity that manufactures, sells, delivers, holds, or offers for sale in commerce a vaginal suppository product containing intentionally added boric acid (CAS nos. 10043-35-3 and 11113-50-1) shall include on the product label the following statement: WARNING: IT IS RECOMMENDED TO CONSULT WITH A DOCTOR BEFORE USE, particularly if you have sensitivity in your lower pelvis or abdomen, a sexually transmitted disease (STD), pelvic inflammatory disease (PID), vaginal bleeding, sores, ulcerations, nausea, fever, or chills. Do not use on broken or irritated skin. Stop use and contact a doctor if symptoms persist or worsen, or if you experience irritation, burning, bleeding, or cramping. NOT FOR ORAL CONSUMPTION. FOR VAGINAL USE ONLY. DO NOT USE IF PREGNANT, TRYING TO CONCEIVE, OR NURSING. IF YOU BECOME PREGNANT WHILE USING THIS PRODUCT, DISCONTINUE USE IMMEDIATELY. If swallowed, get medical help or contact Poison Control Center immediately. Some boric acid suppository products may break down a condomensure product has completely dissolved before having sex.
(2)Commencing January 1, 2035, no person or entity shall manufacture, sell, deliver, hold, or offer for sale in commerce a vaginal suppository product that contains intentionally added boric acid (CAS nos. 10043-35-3 and 11113-50-1).
(3)Paragraphs (1) and (2) shall not apply to a vaginal suppository product containing intentionally added boric acid (CAS nos. 10043-35-3 and 11113-50-1) if the product becomes regulated as a drug by the United States Food and Drug Administration.
SEC. 3.Section 108982 of the Health and Safety Code is amended to read:108982.For purposes of this chapter, the following terms have the following definitions:
(a)Cosmetic product means an article for retail sale or professional use intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to the human body for cleansing, beautifying, promoting attractiveness, or altering the appearance.
(b)Perfluoroalkyl and polyfluoroalkyl substances or PFAS means a class of fluorinated organic chemicals containing at least one fully fluorinated carbon atom.
(c)Intentionally added PFAS means either of the following:
(1)PFAS chemicals that a manufacturer has intentionally added to a product and that have a functional or technical effect on the product.
(2)PFAS chemicals that are intentional breakdown products of an added chemical.
(d)Product label means a display of written, printed, or graphic matter upon a cosmetic product or upon its immediate container.
SEC. 4.Section 2.5 of this bill incorporates amendments to Section 108980 of the Health and Safety Code proposed by both this bill and Assembly Bill 60. That section of this bill shall only become operative if (1) both bills are enacted and become effective on or before January 1, 2026, but this bill becomes operative first, (2) each bill amends Section 108980 of the Health and Safety Code, and (3) this bill is enacted after Assembly Bill 60, in which case Section 108980 of the Health and Safety Code, as amended by Section 2 of this bill, shall remain operative only until the operative date of Assembly Bill 60, at which time Section 2.5 of this bill shall become operative.
SEC. 5.This act is an urgency statute necessary for the immediate preservation of the public peace, health, or safety within the meaning of Article IV of the California Constitution and shall go into immediate effect. The facts constituting the necessity are:
In order for women in this state to have necessary medical and hygiene materials available to them in a timely manner, it is necessary that this act take effect immediately.
The Legislature finds and declares all of the following:
(a)According to published research from Johns Hopkins University, intravaginal boric acid represents one of the few available options for addressing recurrent vaginal yeast and bacterial infections, including infections caused by azole-resistant Candida and nitroimidazole-resistant Trichomoniasis. Intravaginal boric acid is included in multiple national guidelines for addressing infectious vaginitis, including guidelines issued by the American College of Obstetricians and Gynecologists and the federal Centers for Disease Control and Prevention.
(b)Research suggests that intravaginal boric acid is well tolerated for use in addressing recurrent vaginal infections. However, little is known about the safety of intravaginal boric acid use during pregnancy, and animal studies show that high levels of oral exposure are associated with increased risk of birth defects. As a result, guidelines issued by the American College of Obstetricians and Gynecologists and health care professional associations in other countries, including Canada and the United Kingdom, recommend against intravaginal boric acid use during pregnancy, or recommend that persons use reliable contraception while using intravaginal boric acid.
(c)Existing state law bans, beginning January 1, 2027, the manufacture and sale of any cosmetic product containing specified chemicals as intentionally added ingredients, including boric acid. Because the use of intravaginal boric acid represents one of the few available options for addressing recurrent vaginal infections, additional time for vaginal suppository products containing intentionally added boric acid is warranted to allow these products time to become regulated as a drug under the United States Food and Drug Administration.
SEC. 2.Section 108980 of the Health and Safety Code is amended to read:108980.(a)Commencing January 1, 2025, no person or entity shall manufacture, sell, deliver, hold, or offer for sale in commerce any cosmetic product that contains any of the following intentionally added ingredients:
(1)Dibutyl phthalate (CAS no. 84-74-2).
(2)Diethylhexyl phthalate (CAS no. 117-81-7).
(3)Formaldehyde (CAS no. 50-00-0).
(4)Paraformaldehyde (CAS no. 30525-89-4).
(5)Methylene glycol (CAS no. 463-57-0).
(6)Quaternium-15 (CAS no. 51229-78-8).
(7)Mercury (CAS no. 7439-97-6).
(8)Isobutylparaben (CAS no. 4247-02-3).
(9)Isopropylparaben (CAS no. 4191-73-5).
(10)m-Phenylenediamine and its salts (CAS no. 108-45-2).
(11)o-Phenylenediamine and its salts (CAS no. 95-54-5).
(12)The following per- and polyfluoroalkyl substances (PFAS) and their salts:
(A)Perfluorooctane sulfonate (PFOS); heptadecafluorooctane-1-sulfonic acid (CAS no. 1763-23-1).
(B)Potassium perfluorooctanesulfonate; potassium heptadecafluorooctane-1-sulfonate (CAS no. 2795-39-3).
(C)Diethanolamine perfluorooctane sulfonate (CAS 70225-14-8).
(D)Ammonium perfluorooctane sulfonate; ammonium heptadecafluorooctanesulfonate (CAS 29081-56-9).
(E)Lithium perfluorooctane sulfonate; lithium heptadecafluorooctanesulfonate (CAS 29457-72-5).
(F)Perfluorooctanoic acid (PFOA)(CAS no. 335-67-1).
(G)Ammonium pentadecafluorooctanoate (CAS no. 3825-26-1).
(H)Nonadecafluorodecanoic acid (CAS no. 355-76-2).
(I)Ammonium nonadecafluorodecanoate (CAS no. 3108-42-7).
(J)Sodium nonadecafluorodecanoate (CAS no. 3830-45-3).
(K)Perfluorononanoic acid (PFNA)(CAS no. 375-95-1).
(L)Sodium heptadecafluorononanoate (CAS no. 21049-39-8).
(M)Ammonium perfluorononanoate (CAS no. 4149-60-4).
(b)Except as provided in paragraph (2) of subdivision (e), commencing January 1, 2027, no person or entity shall manufacture, sell, deliver, hold, or offer for sale in commerce any cosmetic product that contains any of the following intentionally added ingredients:
(1)Lily aldehyde (CAS no. 80-54-6).
(2)Acetaldehyde (CAS no. 75-07-0).
(3)Cyclohexylamine (CAS no. 108-91-8).
(4)Cyclotetrasiloxane (CAS no. 556-67-2).
(5)Phytonadione (CAS no. 84-80-0).
(6)Sodium perborate (CAS no. 15120-21-5).
(7)Styrene (CAS no. 100-42-5).
(8)Trichloroacetic acid (CAS no. 76-03-9).
(9)Tricresyl phosphate (CAS no. 1330-78-5).
(10)Vinyl acetate (CAS no. 108-05-4).
(11)2-Chloracetamide (CAS no. 79-07-2).
(12)Allyl isothiocyanate (CAS no. 57-06-7).
(13)Anthraquinone (CAS no. 84-65-1).
(14)Malachite green (CAS no. 569-64-2).
(15)Oil from the seeds of Laurus nobilis L. (CAS no. 84603-73-6).
(16)Pyrogallol (CAS no. 87-66-1).
(17)C.I. disperse blue 1 (CAS no. 2475-45-8).
(18)Trisodium nitrilotriacetate (CAS no. 5064-31-3).
(19)The following boron substances:
(A)Perboric acids:
(i)Sodium salt (CAS no. 11138-47-9).
(ii)Sodium salt, monohydrate (CAS no. 12040-72-1).
(iii)Sodium perborate monohydrate (CAS no. 10332-33-9).
(B)Boric acid (CAS nos. 10043-35-3 and 11113-50-1).
(C)Borates, tetraborates, octaborates, and boric acid salts and esters, including all of the following:
(i)Disodium octaborate anhydrous (CAS no. 12008-41-2).
(ii)Disodium octaborate tetrahydrate (CAS no. 12280-03-4).
(iii)2-Aminoethanol, monoester with boric acid (CAS no. 10377-81-8).
(iv)2-Hydroxypropyl ammonium dihydrogen orthoborate (CAS no. 68003-13-4).
(v)Potassium borate, boric acid potassium salt (CAS no. 12712-38-8).
(vi)Trioctyldodecyl borate.
(vii)Zinc borate (CAS no. 1332-07-6).
(viii)Sodium borate, disodium tetraborate anhydrous; boric acid, sodium salt (CAS no. 1330-43-4).
(ix)Tetraboron disodium heptaoxide, hydrate (CAS no. 12267-73-1).
(x)Orthoboric acid, sodium salt (CAS no. 13840-56-7).
(xi)Disodium tetraborate decahydrate; borax decahydrate (CAS no. 1303-96-4).
(xii)Disodium tetraborate pentahydrate; borax pentahydrate (CAS no. 12179-04-3).
(20)C.I. disperse blue 3 (CAS no. 2475-46-9).
(21)Basic green 1 (CAS no. 633-03-4).
(22)Basic blue 7 (CAS no. 2390-60-5).
(23)3(or5)-((4-(benzylmethylamino)phenyl)azo)-1,2 -(or1,4)-dimethyl-1H-1,2,4-triazolium and its salts (CAS nos. 89959-98-8 and 12221-69-1).
(24)Basic violet 4 (CAS no. 2390-59-2).
(25)Basic blue 3 (CAS no. 33203-82-6).
(26)Basic blue 9 (CAS no. 61-73-4).
(c)If a cosmetic product made through manufacturing processes intended to comply with this chapter contains a technically unavoidable trace quantity of an ingredient listed in subdivision (a) or (b) and that trace quantity stems from impurities of natural or synthetic ingredients, the manufacturing process, storage, or migration from packaging, that trace quantity shall not cause the cosmetic product to be in violation of this section.
(d)For purposes of this section, ingredient has the same meaning as defined in Section 111791.5.
(e)(1)Commencing January 1, 2027, a person or entity that manufactures, sells, delivers, holds, or offers for sale in commerce a vaginal suppository product containing intentionally added boric acid (CAS nos. 10043-35-3 and 11113-50-1) shall include on the product label the following statement: WARNING: IT IS RECOMMENDED TO CONSULT WITH A DOCTOR BEFORE USE, particularly if you have sensitivity in your lower pelvis or abdomen, a sexually transmitted disease (STD), pelvic inflammatory disease (PID), vaginal bleeding, sores, ulcerations, nausea, fever, or chills. Do not use on broken or irritated skin. Stop use and contact a doctor if symptoms persist or worsen, or if you experience irritation, burning, bleeding, or cramping. NOT FOR ORAL CONSUMPTION. FOR VAGINAL USE ONLY. DO NOT USE IF PREGNANT, TRYING TO CONCEIVE, OR NURSING. IF YOU BECOME PREGNANT WHILE USING THIS PRODUCT, DISCONTINUE USE IMMEDIATELY. If swallowed, get medical help or contact Poison Control Center immediately. Some boric acid suppository products may break down a condomensure product has completely dissolved before having sex.
(2)Commencing January 1, 2035, no person or entity shall manufacture, sell, deliver, hold, or offer for sale in commerce a vaginal suppository product that contains intentionally added boric acid (CAS nos. 10043-35-3 and 11113-50-1).
(3)Paragraphs (1) and (2) shall not apply to a vaginal suppository product containing intentionally added boric acid (CAS nos. 10043-35-3 and 11113-50-1) if the product becomes regulated as a drug by the United States Food and Drug Administration.
SEC. 2.5.Section 108980 of the Health and Safety Code is amended to read:108980.(a)Commencing January 1, 2025, no a person or entity shall not manufacture, sell, deliver, hold, or offer for sale in commerce any cosmetic product that contains any of the following intentionally added ingredients:
(1)Dibutyl phthalate (CAS no. 84-74-2).
(2)Diethylhexyl phthalate (CAS no. 117-81-7).
(3)Formaldehyde (CAS no. 50-00-0).
(4)Paraformaldehyde (CAS no. 30525-89-4).
(5)Methylene glycol (CAS no. 463-57-0).
(6)Quaternium-15 (CAS no. 51229-78-8).
(7)Mercury (CAS no. 7439-97-6).
(8)Isobutylparaben (CAS no. 4247-02-3).
(9)Isopropylparaben (CAS no. 4191-73-5).
(10)m-Phenylenediamine and its salts (CAS no. 108-45-2).
(11)o-Phenylenediamine and its salts (CAS no. 95-54-5).
(12)The following per- and polyfluoroalkyl substances (PFAS) and their salts:
(A)Perfluorooctane sulfonate (PFOS); heptadecafluorooctane-1-sulfonic acid (CAS no. 1763-23-1).
(B)Potassium perfluorooctanesulfonate; potassium heptadecafluorooctane-1-sulfonate (CAS no. 2795-39-3).
(C)Diethanolamine perfluorooctane sulfonate (CAS 70225-14-8).
(D)Ammonium perfluorooctane sulfonate; ammonium heptadecafluorooctanesulfonate (CAS 29081-56-9).
(E)Lithium perfluorooctane sulfonate; lithium heptadecafluorooctanesulfonate (CAS 29457-72-5).
(F)Perfluorooctanoic acid (PFOA)(CAS no. 335-67-1).
(G)Ammonium pentadecafluorooctanoate (CAS no. 3825-26-1).
(H)Nonadecafluorodecanoic acid (CAS no. 355-76-2).
(I)Ammonium nonadecafluorodecanoate (CAS no. 3108-42-7).
(J)Sodium nonadecafluorodecanoate (CAS no. 3830-45-3).
(K)Perfluorononanoic acid (PFNA)(CAS no. 375-95-1).
(L)Sodium heptadecafluorononanoate (CAS no. 21049-39-8).
(M)Ammonium perfluorononanoate (CAS no. 4149-60-4).
(b)Commencing Except as provided in paragraph (2) of subdivision (f), commencing January 1, 2027, no person or entity shall manufacture, sell, deliver, hold, or offer for sale in commerce any cosmetic product that contains any of the following intentionally added ingredients:
(1)Lily aldehyde (CAS no. 80-54-6).
(2)Acetaldehyde (CAS no. 75-07-0).
(3)Cyclohexylamine (CAS no. 108-91-8).
(4)Cyclotetrasiloxane (CAS no. 556-67-2).
(5)Phytonadione (CAS no. 84-80-0).
(6)Sodium perborate (CAS no. 15120-21-5).
(7)Styrene (CAS no. 100-42-5).
(8)Trichloroacetic acid (CAS no. 76-03-9).
(9)Tricresyl phosphate (CAS no. 1330-78-5).
(10)Vinyl acetate (CAS no. 108-05-4).
(11)2-Chloracetamide (CAS no. 79-07-2).
(12)Allyl isothiocyanate (CAS no. 57-06-7).
(13)Anthraquinone (CAS no. 84-65-1).
(14)Malachite green (CAS no. 569-64-2).
(15)Oil from the seeds of Laurus nobilis L. (CAS no. 84603-73-6).
(16)Pyrogallol (CAS no. 87-66-1).
(17)C.I. disperse blue 1 (CAS no. 2475-45-8).
(18)Trisodium nitrilotriacetate (CAS no. 5064-31-3).
(19)The following boron substances:
(A)Perboric acids:
(i)Sodium salt (CAS no. 11138-47-9).
(ii)Sodium salt, monohydrate (CAS no. 12040-72-1).
(iii)Sodium perborate monohydrate (CAS no. 10332-33-9).
(B)Boric acid (CAS nos. 10043-35-3 and 11113-50-1).
(C)Borates, tetraborates, octaborates, and boric acid salts and esters, including all of the following:
(i)Disodium octaborate anhydrous (CAS no. 12008-41-2).
(ii)Disodium octaborate tetrahydrate (CAS no. 12280-03-4).
(iii)2-Aminoethanol, monoester with boric acid (CAS no. 10377-81-8).
(iv)2-Hydroxypropyl ammonium dihydrogen orthoborate (CAS no. 68003-13-4).
(v)Potassium borate, boric acid potassium salt (CAS no. 12712-38-8).
(vi)Trioctyldodecyl borate.
(vii)Zinc borate (CAS no. 1332-07-6).
(viii)Sodium borate, disodium tetraborate anhydrous; boric acid, sodium salt (CAS no. 1330-43-4).
(ix)Tetraboron disodium heptaoxide, hydrate (CAS no. 12267-73-1).
(x)Orthoboric acid, sodium salt (CAS no. 13840-56-7).
(xi)Disodium tetraborate decahydrate; borax decahydrate (CAS no. 1303-96-4).
(xii)Disodium tetraborate pentahydrate; borax pentahydrate (CAS no. 12179-04-3).
(20)C.I. disperse blue 3 (CAS no. 2475-46-9).
(21)Basic green 1 (CAS no. 633-03-4).
(22)Basic blue 7 (CAS no. 2390-60-5).
(23)3(or5)-((4-(benzylmethylamino)phenyl)azo)-1,2 -(or1,4)-dimethyl-1H-1,2,4-triazolium and its salts (CAS nos. 89959-98-8 and 12221-69-1).
(24)Basic violet 4 (CAS no. 2390-59-2).
(25)Basic blue 3 (CAS no. 33203-82-6).
(26)Basic blue 9 (CAS no. 61-73-4).
(27)Musk ambrette (CAS no. 83-66-9).
(28)Musk tibetene (CAS no.145-39-1).
(29)Musk moskene (CAS no. 116-66-5).
(30)Musk xylene (CAS no. 81-15-2).
(c)(1)Commencing January 1, 2027, a person or entity shall not manufacture, sell, deliver, hold, or offer for sale in commerce a cosmetic product that contains more than 1.4 percent in fine fragrance products, 0.56 percent in eau de toilette, 0 percent in oral products, and 0.042 percent in all other products of musk ketone (CAS no. 81-14-1).
(2)Oral products means a cosmetic product that is intended to be applied on teeth or the mucous membranes of the oral cavity.
(c)(d)If a cosmetic product made through manufacturing processes intended to comply with this chapter contains a technically unavoidable trace quantity of an ingredient listed in subdivision (a) or (b) and that trace quantity stems from impurities of natural or synthetic ingredients, the manufacturing process, storage, or migration from packaging, that trace quantity shall not cause the cosmetic product to be in violation of this section.
(d)(e)For purposes of this section, ingredient has the same meaning as defined in Section 111791.5.
(f)(1)Commencing January 1, 2027, a person or entity that manufactures, sells, delivers, holds, or offers for sale in commerce a vaginal suppository product containing intentionally added boric acid (CAS nos. 10043-35-3 and 11113-50-1) shall include on the product label the following statement: WARNING: IT IS RECOMMENDED TO CONSULT WITH A DOCTOR BEFORE USE, particularly if you have sensitivity in your lower pelvis or abdomen, a sexually transmitted disease (STD), pelvic inflammatory disease (PID), vaginal bleeding, sores, ulcerations, nausea, fever, or chills. Do not use on broken or irritated skin. Stop use and contact a doctor if symptoms persist or worsen, or if you experience irritation, burning, bleeding, or cramping. NOT FOR ORAL CONSUMPTION. FOR VAGINAL USE ONLY. DO NOT USE IF PREGNANT, TRYING TO CONCEIVE, OR NURSING. IF YOU BECOME PREGNANT WHILE USING THIS PRODUCT, DISCONTINUE USE IMMEDIATELY. If swallowed, get medical help or contact Poison Control Center immediately. Some boric acid suppository products may break down a condomensure product has completely dissolved before having sex.
(2)Commencing January 1, 2035, no person or entity shall manufacture, sell, deliver, hold, or offer for sale in commerce a vaginal suppository product that contains intentionally added boric acid (CAS nos. 10043-35-3 and 11113-50-1).
(3)Paragraphs (1) and (2) shall not apply to a vaginal suppository product containing intentionally added boric acid (CAS nos. 10043-35-3 and 11113-50-1) if the product becomes regulated as a drug by the United States Food and Drug Administration.
SEC. 3.Section 108982 of the Health and Safety Code is amended to read:108982.For purposes of this chapter, the following terms have the following definitions:
(a)Cosmetic product means an article for retail sale or professional use intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to the human body for cleansing, beautifying, promoting attractiveness, or altering the appearance.
(b)Perfluoroalkyl and polyfluoroalkyl substances or PFAS means a class of fluorinated organic chemicals containing at least one fully fluorinated carbon atom.
(c)Intentionally added PFAS means either of the following:
(1)PFAS chemicals that a manufacturer has intentionally added to a product and that have a functional or technical effect on the product.
(2)PFAS chemicals that are intentional breakdown products of an added chemical.
(d)Product label means a display of written, printed, or graphic matter upon a cosmetic product or upon its immediate container.
SEC. 4.Section 2.5 of this bill incorporates amendments to Section 108980 of the Health and Safety Code proposed by both this bill and Assembly Bill 60. That section of this bill shall only become operative if (1) both bills are enacted and become effective on or before January 1, 2026, but this bill becomes operative first, (2) each bill amends Section 108980 of the Health and Safety Code, and (3) this bill is enacted after Assembly Bill 60, in which case Section 108980 of the Health and Safety Code, as amended by Section 2 of this bill, shall remain operative only until the operative date of Assembly Bill 60, at which time Section 2.5 of this bill shall become operative.
SEC. 4.SEC. 5.This act is an urgency statute necessary for the immediate preservation of the public peace, health, or safety within the meaning of Article IV of the California Constitution and shall go into immediate effect. The facts constituting the necessity are:
In order for women in this state to have necessary medical and hygiene materials available to them in a timely manner, it is necessary that this act take effect immediately.
The Legislature finds and declares all of the following:
(a)Boric acid is a naturally occurring, mild acid that has been used for decades to successfully address vaginal odor.(b)Gelatin capsules of boric acid, referred to by doctors as Boric Acid Suppositories (BAS), are currently an easy to access, easy to use formulation.(c)Prior to 2014, BAS were primarily only available through compounding pharmacies and were costly. Today, BAS are widely available at retail facilities and are an affordable, effective solution for feminine hygiene.(d)Vaginal odor is one of the top two reasons women visit the doctor.(e)The American College of Obstetricians and Gynecologists recommends the use of BAS and the Centers for Disease Control and Prevention recommend the use of BAS in their published 2015 sexually transmitted diseases treatment guidelines.(f)Existing law bans the manufacture and sale of specified chemicals in cosmetic products, including products that contain boric acid. Because the use of boric acid in BAS has been determined to be effective, BAS products that contain boric acid should be allowed if the product is undergoing clinical trials, is regulated by the United States Food and Drug Administration or has a pending application for regulation, or has been deemed to be safe in third-party placebo-controlled double-blind safety trials.(a)According to published research from Johns Hopkins University, intravaginal boric acid represents one of the few available options for addressing recurrent vaginal yeast and bacterial infections, including infections caused by azole-resistant Candida and nitroimidazole-resistant Trichomoniasis. Intravaginal boric acid is included in multiple national guidelines for addressing infectious vaginitis, including guidelines issued by the American College of Obstetricians and Gynecologists and the federal Centers for Disease Control and Prevention.
(b)Research suggests that intravaginal boric acid is well tolerated for use in addressing recurrent vaginal infections. However, little is known about the safety of intravaginal boric acid use during pregnancy, and animal studies show that high levels of oral exposure are associated with increased risk of birth defects. As a result, guidelines issued by the American College of Obstetricians and Gynecologists and health care professional associations in other countries, including Canada and the United Kingdom, recommend against intravaginal boric acid use during pregnancy, or recommend that persons use reliable contraception while using intravaginal boric acid.
(c)Existing state law bans, beginning January 1, 2027, the manufacture and sale of any cosmetic product containing specified chemicals as intentionally added ingredients, including boric acid. Because the use of intravaginal boric acid represents one of the few available options for addressing recurrent vaginal infections, additional time for vaginal suppository products containing intentionally added boric acid is warranted to allow these products time to become regulated as a drug under the United States Food and Drug Administration.
SEC. 2.Section 108980 of the Health and Safety Code is amended to read:108980.(a)Commencing January 1, 2025, no person or entity shall manufacture, sell, deliver, hold, or offer for sale in commerce any cosmetic product that contains any of the following intentionally added ingredients:
(1)Dibutyl phthalate (CAS no. 84-74-2).
(2)Diethylhexyl phthalate (CAS no. 117-81-7).
(3)Formaldehyde (CAS no. 50-00-0).
(4)Paraformaldehyde (CAS no. 30525-89-4).
(5)Methylene glycol (CAS no. 463-57-0).
(6)Quaternium-15 (CAS no. 51229-78-8).
(7)Mercury (CAS no. 7439-97-6).
(8)Isobutylparaben (CAS no. 4247-02-3).
(9)Isopropylparaben (CAS no. 4191-73-5).
(10)m-Phenylenediamine and its salts (CAS no. 108-45-2).
(11)o-Phenylenediamine and its salts (CAS no. 95-54-5).
(12)The following per- and polyfluoroalkyl substances (PFAS) and their salts:
(A)Perfluorooctane sulfonate (PFOS); heptadecafluorooctane-1-sulfonic acid (CAS no. 1763-23-1).
(B)Potassium perfluorooctanesulfonate; potassium heptadecafluorooctane-1-sulfonate (CAS no. 2795-39-3).
(C)Diethanolamine perfluorooctane sulfonate (CAS 70225-14-8).
(D)Ammonium perfluorooctane sulfonate; ammonium heptadecafluorooctanesulfonate (CAS 29081-56-9).
(E)Lithium perfluorooctane sulfonate; lithium heptadecafluorooctanesulfonate (CAS 29457-72-5).
(F)Perfluorooctanoic acid (PFOA)(CAS no. 335-67-1).
(G)Ammonium pentadecafluorooctanoate (CAS no. 3825-26-1).
(H)Nonadecafluorodecanoic acid (CAS no. 355-76-2).
(I)Ammonium nonadecafluorodecanoate (CAS no. 3108-42-7).
(J)Sodium nonadecafluorodecanoate (CAS no. 3830-45-3).
(K)Perfluorononanoic acid (PFNA)(CAS no. 375-95-1).
(L)Sodium heptadecafluorononanoate (CAS no. 21049-39-8).
(M)Ammonium perfluorononanoate (CAS no. 4149-60-4).
(b)Commencing Except as provided in paragraph (2) of subdivision (e), commencing January 1, 2027, no person or entity shall manufacture, sell, deliver, hold, or offer for sale in commerce any cosmetic product that contains any of the following intentionally added ingredients:
(1)Lily aldehyde (CAS no. 80-54-6).
(2)Acetaldehyde (CAS no. 75-07-0).
(3)Cyclohexylamine (CAS no. 108-91-8).
(4)Cyclotetrasiloxane (CAS no. 556-67-2).
(5)Phytonadione (CAS no. 84-80-0).
(6)Sodium perborate (CAS no. 15120-21-5).
(7)Styrene (CAS no. 100-42-5).
(8)Trichloroacetic acid (CAS no. 76-03-9).
(9)Tricresyl phosphate (CAS no. 1330-78-5).
(10)Vinyl acetate (CAS no. 108-05-4).
(11)2-Chloracetamide (CAS no. 79-07-2).
(12)Allyl isothiocyanate (CAS no. 57-06-7).
(13)Anthraquinone (CAS no. 84-65-1).
(14)Malachite green (CAS no. 569-64-2).
(15)Oil from the seeds of Laurus nobilis L. (CAS no. 84603-73-6).
(16)Pyrogallol (CAS no. 87-66-1).
(17)C.I. disperse blue 1 (CAS no. 2475-45-8).
(18)Trisodium nitrilotriacetate (CAS no. 5064-31-3).
(19)The following boron substances:
(A)Perboric acids:
(i)Sodium salt (CAS no. 11138-47-9).
(ii)Sodium salt, monohydrate (CAS no. 12040-72-1).
(iii)Sodium perborate monohydrate (CAS no. 10332-33-9).
(B)Boric acid (CAS nos. 10043-35-3 and 11113-50-1).
(C)Borates, tetraborates, octaborates, and boric acid salts and esters, including all of the following:
(i)Disodium octaborate anhydrous (CAS no. 12008-41-2).
(ii)Disodium octaborate tetrahydrate (CAS no. 12280-03-4).
(iii)2-Aminoethanol, monoester with boric acid (CAS no. 10377-81-8).
(iv)2-Hydroxypropyl ammonium dihydrogen orthoborate (CAS no. 68003-13-4).
(v)Potassium borate, boric acid potassium salt (CAS no. 12712-38-8).
(vi)Trioctyldodecyl borate.
(vii)Zinc borate (CAS no. 1332-07-6).
(viii)Sodium borate, disodium tetraborate anhydrous; boric acid, sodium salt (CAS no. 1330-43-4).
(ix)Tetraboron disodium heptaoxide, hydrate (CAS no. 12267-73-1).
(x)Orthoboric acid, sodium salt (CAS no. 13840-56-7).
(xi)Disodium tetraborate decahydrate; borax decahydrate (CAS no. 1303-96-4).
(xii)Disodium tetraborate pentahydrate; borax pentahydrate (CAS no. 12179-04-3).
(20)C.I. disperse blue 3 (CAS no. 2475-46-9).
(21)Basic green 1 (CAS no. 633-03-4).
(22)Basic blue 7 (CAS no. 2390-60-5).
(23)3(or5)-((4-(benzylmethylamino)phenyl)azo)-1,2 -(or1,4)-dimethyl-1H-1,2,4-triazolium and its salts (CAS nos. 89959-98-8 and 12221-69-1).
(24)Basic violet 4 (CAS no. 2390-59-2).
(25)Basic blue 3 (CAS no. 33203-82-6).
(26)Basic blue 9 (CAS no. 61-73-4).
(c)If a cosmetic product made through manufacturing processes intended to comply with this chapter contains a technically unavoidable trace quantity of an ingredient listed in subdivision (a) or (b) and that trace quantity stems from impurities of natural or synthetic ingredients, the manufacturing process, storage, or migration from packaging, that trace quantity shall not cause the cosmetic product to be in violation of this section.
(d)For purposes of this section, ingredient has the same meaning as defined in Section 111791.5.
(e)The prohibition in subparagraph (B) of paragraph (19) of subdivision (b) shall not apply to a vaginal suppository if any of the following are true:(1)The product is undergoing clinical trials for regulation by the United States Food and Drug Administration.(2)The product has a pending new drug application under Section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355).(3)The product becomes regulated as a drug by the United States Food and Drug Administration.(4)The product has passed definitive third-party placebo-controlled double-blind safety trials. If third-party placebo-controlled double-blind clinical data demonstrates that the product is not safe, the prohibition in subparagraph (B) of paragraph (19) of subdivision (b) shall apply.(e)(1)Commencing January 1, 2027, a person or entity that manufactures, sells, delivers, holds, or offers for sale in commerce a vaginal suppository product containing intentionally added boric acid (CAS nos. 10043-35-3 and 11113-50-1) shall include on the product label the following statement: WARNING: IT IS RECOMMENDED TO CONSULT WITH A DOCTOR BEFORE USE, particularly if you have sensitivity in your lower pelvis or abdomen, a sexually transmitted disease (STD), pelvic inflammatory disease (PID), vaginal bleeding, sores, ulcerations, nausea, fever, or chills. Do not use on broken or irritated skin. Stop use and contact a doctor if symptoms persist or worsen, or if you experience irritation, burning, bleeding, or cramping. NOT FOR ORAL CONSUMPTION. FOR VAGINAL USE ONLY. DO NOT USE IF PREGNANT, TRYING TO CONCEIVE, OR NURSING. IF YOU BECOME PREGNANT WHILE USING THIS PRODUCT, DISCONTINUE USE IMMEDIATELY. If swallowed, get medical help or contact Poison Control Center immediately. Some boric acid suppository products may break down a condomensure product has completely dissolved before having sex.
(2)Commencing January 1, 2035, no person or entity shall manufacture, sell, deliver, hold, or offer for sale in commerce a vaginal suppository product that contains intentionally added boric acid (CAS nos. 10043-35-3 and 11113-50-1).
(3)Paragraphs (1) and (2) shall not apply to a vaginal suppository product containing intentionally added boric acid (CAS nos. 10043-35-3 and 11113-50-1) if the product becomes regulated as a drug by the United States Food and Drug Administration.
SEC. 3.Section 108982 of the Health and Safety Code is amended to read:108982.For purposes of this chapter, the following terms have the following definitions:
(a)Cosmetic product means an article for retail sale or professional use intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to the human body for cleansing, beautifying, promoting attractiveness, or altering the appearance.
(b)Perfluoroalkyl and polyfluoroalkyl substances or PFAS means a class of fluorinated organic chemicals containing at least one fully fluorinated carbon atom.
(c)Intentionally added PFAS means either of the following:
(1)PFAS chemicals that a manufacturer has intentionally added to a product and that have a functional or technical effect on the product.
(2)PFAS chemicals that are intentional breakdown products of an added chemical.
(d)Product label means a display of written, printed, or graphic matter upon a cosmetic product or upon its immediate container.
SEC. 3.SEC. 4.This act is an urgency statute necessary for the immediate preservation of the public peace, health, or safety within the meaning of Article IV of the California Constitution and shall go into immediate effect. The facts constituting the necessity are:
In order for women in this state to have necessary medical and hygiene materials available to them in a timely manner, it is necessary that this act take effect immediately.
The Legislature finds and declares all of the following:
(a)Boric acid is a naturally occurring, mild acid that has been used for decades to successfully address vaginal odor.
(b)Gelatin capsules of boric acid, referred to by doctors as Boric Acid Suppositories (BAS), are currently an easy to access, easy to use formulation.
(c)Prior to 2014, BAS were primarily only available through compounding pharmacies and were costly. Today, BAS are widely available at retail facilities and are an affordable, effective solution for feminine hygiene.
(d)Vaginal odor is one of the top two reasons women visit the doctor.
(e)The American College of Obstetricians and Gynecologists recommends the use of BAS and the Centers for Disease Control and Prevention recommend the use of BAS in their published 2015 sexually transmitted diseases treatment guidelines.
(f)Existing law bans the manufacture and sale of specified chemicals in cosmetic products, including products that contain boric acid. Because the use of boric acid in BAS has been determined to be effective, BAS products that contain boric acid should be allowed if the product is undergoing clinical trials, is regulated by the United States Food and Drug Administration or has a pending application for regulation, or has been deemed to be safe in third-party placebo-controlled double-blind safety trials.
SEC. 2.Section 108980 of the Health and Safety Code is amended to read:108980.(a)Commencing January 1, 2025, no person or entity shall manufacture, sell, deliver, hold, or offer for sale in commerce any cosmetic product that contains any of the following intentionally added ingredients:
(1)Dibutyl phthalate (CAS no. 84-74-2).
(2)Diethylhexyl phthalate (CAS no. 117-81-7).
(3)Formaldehyde (CAS no. 50-00-0).
(4)Paraformaldehyde (CAS no. 30525-89-4).
(5)Methylene glycol (CAS no. 463-57-0).
(6)Quaternium-15 (CAS no. 51229-78-8).
(7)Mercury (CAS no. 7439-97-6).
(8)Isobutylparaben (CAS no. 4247-02-3).
(9)Isopropylparaben (CAS no. 4191-73-5).
(10)m-Phenylenediamine and its salts (CAS no. 108-45-2).
(11)o-Phenylenediamine and its salts (CAS no. 95-54-5).
(12)The following per- and polyfluoroalkyl substances (PFAS) and their salts:
(A)Perfluorooctane sulfonate (PFOS); heptadecafluorooctane-1-sulfonic acid (CAS no. 1763-23-1).
(B)Potassium perfluorooctanesulfonate; potassium heptadecafluorooctane-1-sulfonate (CAS no. 2795-39-3).
(C)Diethanolamine perfluorooctane sulfonate (CAS 70225-14-8).
(D)Ammonium perfluorooctane sulfonate; ammonium heptadecafluorooctanesulfonate (CAS 29081-56-9).
(E)Lithium perfluorooctane sulfonate; lithium heptadecafluorooctanesulfonate (CAS 29457-72-5).
(F)Perfluorooctanoic acid (PFOA)(CAS no. 335-67-1).
(G)Ammonium pentadecafluorooctanoate (CAS no. 3825-26-1).
(H)Nonadecafluorodecanoic acid (CAS no. 355-76-2).
(I)Ammonium nonadecafluorodecanoate (CAS no. 3108-42-7).
(J)Sodium nonadecafluorodecanoate (CAS no. 3830-45-3).
(K)Perfluorononanoic acid (PFNA)(CAS no. 375-95-1).
(L)Sodium heptadecafluorononanoate (CAS no. 21049-39-8).
(M)Ammonium perfluorononanoate (CAS no. 4149-60-4).
(b)Commencing January 1, 2027, no person or entity shall manufacture, sell, deliver, hold, or offer for sale in commerce any cosmetic product that contains any of the following intentionally added ingredients:
(1)Lily aldehyde (CAS no. 80-54-6).
(2)Acetaldehyde (CAS no. 75-07-0).
(3)Cyclohexylamine (CAS no. 108-91-8).
(4)Cyclotetrasiloxane (CAS no. 556-67-2).
(5)Phytonadione (CAS no. 84-80-0).
(6)Sodium perborate (CAS no. 15120-21-5).
(7)Styrene (CAS no. 100-42-5).
(8)Trichloroacetic acid (CAS no. 76-03-9).
(9)Tricresyl phosphate (CAS no. 1330-78-5).
(10)Vinyl acetate (CAS no. 108-05-4).
(11)2-Chloracetamide (CAS no. 79-07-2).
(12)Allyl isothiocyanate (CAS no. 57-06-7).
(13)Anthraquinone (CAS no. 84-65-1).
(14)Malachite green (CAS no. 569-64-2).
(15)Oil from the seeds of Laurus nobilis L. (CAS no. 84603-73-6).
(16)Pyrogallol (CAS no. 87-66-1).
(17)C.I. disperse blue 1 (CAS no. 2475-45-8).
(18)Trisodium nitrilotriacetate (CAS no. 5064-31-3).
(19)The following boron substances:
(A)Perboric acids:
(i)Sodium salt (CAS no. 11138-47-9).
(ii)Sodium salt, monohydrate (CAS no. 12040-72-1).
(iii)Sodium perborate monohydrate (CAS no. 10332-33-9).
(B)Boric acid (CAS nos. 10043-35-3 and 11113-50-1).
(C)Borates, tetraborates, octaborates, and boric acid salts and esters, including all of the following:
(i)Disodium octaborate anhydrous (CAS no. 12008-41-2).
(ii)Disodium octaborate tetrahydrate (CAS no. 12280-03-4).
(iii)2-Aminoethanol, monoester with boric acid (CAS no. 10377-81-8).
(iv)2-Hydroxypropyl ammonium dihydrogen orthoborate (CAS no. 68003-13-4).
(v)Potassium borate, boric acid potassium salt (CAS no. 12712-38-8).
(vi)Trioctyldodecyl borate.
(vii)Zinc borate (CAS no. 1332-07-6).
(viii)Sodium borate, disodium tetraborate anhydrous; boric acid, sodium salt (CAS no. 1330-43-4).
(ix)Tetraboron disodium heptaoxide, hydrate (CAS no. 12267-73-1).
(x)Orthoboric acid, sodium salt (CAS no. 13840-56-7).
(xi)Disodium tetraborate decahydrate; borax decahydrate (CAS no. 1303-96-4).
(xii)Disodium tetraborate pentahydrate; borax pentahydrate (CAS no. 12179-04-3).
(20)C.I. disperse blue 3 (CAS no. 2475-46-9).
(21)Basic green 1 (CAS no. 633-03-4).
(22)Basic blue 7 (CAS no. 2390-60-5).
(23)3(or5)-((4-(benzylmethylamino)phenyl)azo)-1,2 -(or1,4)-dimethyl-1H-1,2,4-triazolium and its salts (CAS nos. 89959-98-8 and 12221-69-1).
(24)Basic violet 4 (CAS no. 2390-59-2).
(25)Basic blue 3 (CAS no. 33203-82-6).
(26)Basic blue 9 (CAS no. 61-73-4).
(c)If a cosmetic product made through manufacturing processes intended to comply with this chapter contains a technically unavoidable trace quantity of an ingredient listed in subdivision (a) or (b) and that trace quantity stems from impurities of natural or synthetic ingredients, the manufacturing process, storage, or migration from packaging, that trace quantity shall not cause the cosmetic product to be in violation of this section.
(d)For purposes of this section, ingredient has the same meaning as defined in Section 111791.5.
(e)The prohibition in subparagraph (B) of paragraph (19) of subdivision (b) shall not apply to a vaginal or vulvar product suppository if any of the following are true:
(1)The product is undergoing clinical trials for regulation by the United States Food and Drug Administration.
(2)The product has a pending new drug application under Section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355).
(3)The product becomes regulated as a drug by the United States Food and Drug Administration.
(4)The product has passed definitive third-party placebo-controlled double-blind safety trials. If third-party placebo-controlled double-blind clinical data demonstrates that the product is not safe, the prohibition in subparagraph (B) of paragraph (19) of subdivision (b) shall apply.
SEC. 3.This act is an urgency statute necessary for the immediate preservation of the public peace, health, or safety within the meaning of Article IV of the California Constitution and shall go into immediate effect. The facts constituting the necessity are:
In order for women in this state to have necessary medical and hygiene materials available to them in a timely manner, it is necessary that this act take effect immediately.
The Legislature finds and declares all of the following:
(a)Boric acid is a naturally occurring, mild acid that has been used for decades to successfully address vaginal odor.
(b)Gelatin capsules of boric acid, referred to by doctors as Boric Acid Suppositories (BAS), are currently an easy to access, easy to use formulation.
(c)Prior to 2014, BAS were primarily only available through compounding pharmacies and were costly. Today, BAS are widely available at retail facilities and are an affordable, effective solution for feminine hygiene.
(d)Vaginal odor is one of the top two reasons women visit the doctor.
(e)The American College of Obstetricians and Gynecologists recommends the use of BAS and the Centers for Disease Control and Prevention recommend the use of BAS in their published 2015 sexually transmitted diseases treatment guidelines.
SEC. 2.Section 108980 of the Health and Safety Code is amended to read:108980.(a)Commencing January 1, 2025, no person or entity shall manufacture, sell, deliver, hold, or offer for sale in commerce any cosmetic product that contains any of the following intentionally added ingredients:
(1)Dibutyl phthalate (CAS no. 84-74-2).
(2)Diethylhexyl phthalate (CAS no. 117-81-7).
(3)Formaldehyde (CAS no. 50-00-0).
(4)Paraformaldehyde (CAS no. 30525-89-4).
(5)Methylene glycol (CAS no. 463-57-0).
(6)Quaternium-15 (CAS no. 51229-78-8).
(7)Mercury (CAS no. 7439-97-6).
(8)Isobutylparaben (CAS no. 4247-02-3).
(9)Isopropylparaben (CAS no. 4191-73-5).
(10)m-Phenylenediamine and its salts (CAS no. 108-45-2).
(11)o-Phenylenediamine and its salts (CAS no. 95-54-5).
(12)The following per- and polyfluoroalkyl substances (PFAS) and their salts:
(A)Perfluorooctane sulfonate (PFOS); heptadecafluorooctane-1-sulfonic acid (CAS no. 1763-23-1).
(B)Potassium perfluorooctanesulfonate; potassium heptadecafluorooctane-1-sulfonate (CAS no. 2795-39-3).
(C)Diethanolamine perfluorooctane sulfonate (CAS 70225-14-8).
(D)Ammonium perfluorooctane sulfonate; ammonium heptadecafluorooctanesulfonate (CAS 29081-56-9).
(E)Lithium perfluorooctane sulfonate; lithium heptadecafluorooctanesulfonate (CAS 29457-72-5).
(F)Perfluorooctanoic acid (PFOA)(CAS no. 335-67-1).
(G)Ammonium pentadecafluorooctanoate (CAS no. 3825-26-1).
(H)Nonadecafluorodecanoic acid (CAS no. 355-76-2).
(I)Ammonium nonadecafluorodecanoate (CAS no. 3108-42-7).
(J)Sodium nonadecafluorodecanoate (CAS no. 3830-45-3).
(K)Perfluorononanoic acid (PFNA)(CAS no. 375-95-1).
(L)Sodium heptadecafluorononanoate (CAS no. 21049-39-8).
(M)Ammonium perfluorononanoate (CAS no. 4149-60-4).
(b)Commencing January 1, 2027, no person or entity shall manufacture, sell, deliver, hold, or offer for sale in commerce any cosmetic product that contains any of the following intentionally added ingredients:
(1)Lily aldehyde (CAS no. 80-54-6).
(2)Acetaldehyde (CAS no. 75-07-0).
(3)Cyclohexylamine (CAS no. 108-91-8).
(4)Cyclotetrasiloxane (CAS no. 556-67-2).
(5)Phytonadione (CAS no. 84-80-0).
(6)Sodium perborate (CAS no. 15120-21-5).
(7)Styrene (CAS no. 100-42-5).
(8)Trichloroacetic acid (CAS no. 76-03-9).
(9)Tricresyl phosphate (CAS no. 1330-78-5).
(10)Vinyl acetate (CAS no. 108-05-4).
(11)2-Chloracetamide (CAS no. 79-07-2).
(12)Allyl isothiocyanate (CAS no. 57-06-7).
(13)Anthraquinone (CAS no. 84-65-1).
(14)Malachite green (CAS no. 569-64-2).
(15)Oil from the seeds of Laurus nobilis L. (CAS no. 84603-73-6).
(16)Pyrogallol (CAS no. 87-66-1).
(17)C.I. disperse blue 1 (CAS no. 2475-45-8).
(18)Trisodium nitrilotriacetate (CAS no. 5064-31-3).
(19)The following boron substances:
(A)Perboric acids:
(i)Sodium salt (CAS no. 11138-47-9).
(ii)Sodium salt, monohydrate (CAS no. 12040-72-1).
(iii)Sodium perborate monohydrate (CAS no. 10332-33-9).
(B)Boric acid (CAS nos. 10043-35-3 and 11113-50-1).
(C)Borates, tetraborates, octaborates, and boric acid salts and esters, including all of the following:
(i)Disodium octaborate anhydrous (CAS no. 12008-41-2).
(ii)Disodium octaborate tetrahydrate (CAS no. 12280-03-4).
(iii)2-Aminoethanol, monoester with boric acid (CAS no. 10377-81-8).
(iv)2-Hydroxypropyl ammonium dihydrogen orthoborate (CAS no. 68003-13-4).
(v)Potassium borate, boric acid potassium salt (CAS no. 12712-38-8).
(vi)Trioctyldodecyl borate.
(vii)Zinc borate (CAS no. 1332-07-6).
(viii)Sodium borate, disodium tetraborate anhydrous; boric acid, sodium salt (CAS no. 1330-43-4).
(ix)Tetraboron disodium heptaoxide, hydrate (CAS no. 12267-73-1).
(x)Orthoboric acid, sodium salt (CAS no. 13840-56-7).
(xi)Disodium tetraborate decahydrate; borax decahydrate (CAS no. 1303-96-4).
(xii)Disodium tetraborate pentahydrate; borax pentahydrate (CAS no. 12179-04-3).
(20)C.I. disperse blue 3 (CAS no. 2475-46-9).
(21)Basic green 1 (CAS no. 633-03-4).
(22)Basic blue 7 (CAS no. 2390-60-5).
(23)3(or5)-((4-(benzylmethylamino)phenyl)azo)-1,2 -(or1,4)-dimethyl-1H-1,2,4-triazolium and its salts (CAS nos. 89959-98-8 and 12221-69-1).
(24)Basic violet 4 (CAS no. 2390-59-2).
(25)Basic blue 3 (CAS no. 33203-82-6).
(26)Basic blue 9 (CAS no. 61-73-4).
(c)If a cosmetic product made through manufacturing processes intended to comply with this chapter contains a technically unavoidable trace quantity of an ingredient listed in subdivision (a) or (b) and that trace quantity stems from impurities of natural or synthetic ingredients, the manufacturing process, storage, or migration from packaging, that trace quantity shall not cause the cosmetic product to be in violation of this section.
(d)For purposes of this section, ingredient has the same meaning as defined in Section 111791.5.
(e)The prohibition in subparagraph (B) of paragraph (19) of subdivision (b) shall not apply to a vaginal or vulvar product if any of the following are true:
(1)The product is undergoing clinical trials for regulation by the United States Food and Drug Administration.
(2)The product has a pending new drug application under Section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355).
(3)The product becomes regulated as a drug by the United States Food and Drug Administration.
(4)The product has passed definitive third-party placebo-controlled double-blind safety trials. If third-party placebo-controlled double-blind clinical data demonstrates that the product is not safe, the prohibition in subparagraph (B) of paragraph (19) of subdivision (b) shall apply.
SEC. 3.This act is an urgency statute necessary for the immediate preservation of the public peace, health, or safety within the meaning of Article IV of the California Constitution and shall go into immediate effect. The facts constituting the necessity are:
In order for women in this state to have necessary medical and hygiene materials available to them in a timely manner, it is necessary that this act take effect immediately.
The Legislature finds and declares all of the following:
(a)Boric acid is a naturally occurring, mild acid that has been used for decades to successfully address vaginal odor.
(b)Gelatin capsules of boric acid, referred to by doctors as Boric Acid Suppositories (BAS), are currently an easy to access, easy to use formulation.
(c)Prior to 2014, BAS were primarily only available through compounding pharmacies and were costly. Today, BAS are widely available at retail facilities and are an affordable, effective solution for feminine hygiene.
(d)Vaginal odor is one of the top two reasons women visit the doctor.
(e)The American College of Obstetricians and Gynecologists recommends the use of BAS and the Centers for Disease Control and Prevention recommend the use of BAS in their published 2015 sexually transmitted diseases treatment guidelines.
SEC. 2.Section 108980 of the Health and Safety Code is amended to read:108980.(a)Commencing January 1, 2025, no person or entity shall manufacture, sell, deliver, hold, or offer for sale in commerce any cosmetic product that contains any of the following intentionally added ingredients:
(1)Dibutyl phthalate (CAS no. 84-74-2).
(2)Diethylhexyl phthalate (CAS no. 117-81-7).
(3)Formaldehyde (CAS no. 50-00-0).
(4)Paraformaldehyde (CAS no. 30525-89-4).
(5)Methylene glycol (CAS no. 463-57-0).
(6)Quaternium-15 (CAS no. 51229-78-8).
(7)Mercury (CAS no. 7439-97-6).
(8)Isobutylparaben (CAS no. 4247-02-3).
(9)Isopropylparaben (CAS no. 4191-73-5).
(10)m-Phenylenediamine and its salts (CAS no. 108-45-2).
(11)o-Phenylenediamine and its salts (CAS no. 95-54-5).
(12)The following per- and polyfluoroalkyl substances (PFAS) and their salts:
(A)Perfluorooctane sulfonate (PFOS); heptadecafluorooctane-1-sulfonic acid (CAS no. 1763-23-1).
(B)Potassium perfluorooctanesulfonate; potassium heptadecafluorooctane-1-sulfonate (CAS no. 2795-39-3).
(C)Diethanolamine perfluorooctane sulfonate (CAS 70225-14-8).
(D)Ammonium perfluorooctane sulfonate; ammonium heptadecafluorooctanesulfonate (CAS 29081-56-9).
(E)Lithium perfluorooctane sulfonate; lithium heptadecafluorooctanesulfonate (CAS 29457-72-5).
(F)Perfluorooctanoic acid (PFOA)(CAS no. 335-67-1).
(G)Ammonium pentadecafluorooctanoate (CAS no. 3825-26-1).
(H)Nonadecafluorodecanoic acid (CAS no. 355-76-2).
(I)Ammonium nonadecafluorodecanoate (CAS no. 3108-42-7).
(J)Sodium nonadecafluorodecanoate (CAS no. 3830-45-3).
(K)Perfluorononanoic acid (PFNA)(CAS no. 375-95-1).
(L)Sodium heptadecafluorononanoate (CAS no. 21049-39-8).
(M)Ammonium perfluorononanoate (CAS no. 4149-60-4).
(b)Commencing January 1, 2027, no person or entity shall manufacture, sell, deliver, hold, or offer for sale in commerce any cosmetic product that contains any of the following intentionally added ingredients:
(1)Lily aldehyde (CAS no. 80-54-6).
(2)Acetaldehyde (CAS no. 75-07-0).
(3)Cyclohexylamine (CAS no. 108-91-8).
(4)Cyclotetrasiloxane (CAS no. 556-67-2).
(5)Phytonadione (CAS no. 84-80-0).
(6)Sodium perborate (CAS no. 15120-21-5).
(7)Styrene (CAS no. 100-42-5).
(8)Trichloroacetic acid (CAS no. 76-03-9).
(9)Tricresyl phosphate (CAS no. 1330-78-5).
(10)Vinyl acetate (CAS no. 108-05-4).
(11)2-Chloracetamide (CAS no. 79-07-2).
(12)Allyl isothiocyanate (CAS no. 57-06-7).
(13)Anthraquinone (CAS no. 84-65-1).
(14)Malachite green (CAS no. 569-64-2).
(15)Oil from the seeds of Laurus nobilis L. (CAS no. 84603-73-6).
(16)Pyrogallol (CAS no. 87-66-1).
(17)C.I. disperse blue 1 (CAS no. 2475-45-8).
(18)Trisodium nitrilotriacetate (CAS no. 5064-31-3).
(19)The following boron substances:
(A)Perboric acids:
(i)Sodium salt (CAS no. 11138-47-9).
(ii)Sodium salt, monohydrate (CAS no. 12040-72-1).
(iii)Sodium perborate monohydrate (CAS no. 10332-33-9).
(B)Boric acid (CAS nos. 10043-35-3 and 11113-50-1).
(C)Borates, tetraborates, octaborates, and boric acid salts and esters, including all of the following:
(i)Disodium octaborate anhydrous (CAS no. 12008-41-2).
(ii)Disodium octaborate tetrahydrate (CAS no. 12280-03-4).
(iii)2-Aminoethanol, monoester with boric acid (CAS no. 10377-81-8).
(iv)2-Hydroxypropyl ammonium dihydrogen orthoborate (CAS no. 68003-13-4).
(v)Potassium borate, boric acid potassium salt (CAS no. 12712-38-8).
(vi)Trioctyldodecyl borate.
(vii)Zinc borate (CAS no. 1332-07-6).
(viii)Sodium borate, disodium tetraborate anhydrous; boric acid, sodium salt (CAS no. 1330-43-4).
(ix)Tetraboron disodium heptaoxide, hydrate (CAS no. 12267-73-1).
(x)Orthoboric acid, sodium salt (CAS no. 13840-56-7).
(xi)Disodium tetraborate decahydrate; borax decahydrate (CAS no. 1303-96-4).
(xii)Disodium tetraborate pentahydrate; borax pentahydrate (CAS no. 12179-04-3).
(20)C.I. disperse blue 3 (CAS no. 2475-46-9).
(21)Basic green 1 (CAS no. 633-03-4).
(22)Basic blue 7 (CAS no. 2390-60-5).
(23)3(or5)-((4-(benzylmethylamino)phenyl)azo)-1,2 -(or1,4)-dimethyl-1H-1,2,4-triazolium and its salts (CAS nos. 89959-98-8 and 12221-69-1).
(24)Basic violet 4 (CAS no. 2390-59-2).
(25)Basic blue 3 (CAS no. 33203-82-6).
(26)Basic blue 9 (CAS no. 61-73-4).
(c)If a cosmetic product made through manufacturing processes intended to comply with this chapter contains a technically unavoidable trace quantity of an ingredient listed in subdivision (a) or (b) and that trace quantity stems from impurities of natural or synthetic ingredients, the manufacturing process, storage, or migration from packaging, that trace quantity shall not cause the cosmetic product to be in violation of this section.
(d)For purposes of this section, ingredient has the same meaning as defined in Section 111791.5.
(e)The prohibition in subparagraph (B) of paragraph (19) of subdivision (b) shall not apply to a vaginal or vulvar product if any of the following are true:
(1)The product is undergoing clinical trials for regulation by the United States Food and Drug Administration.
(2)The product has a pending new drug application under Section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355).
(3)The product becomes regulated as a drug by the United States Food and Drug Administration.
(4)The product has passed definitive third-party placebo-controlled double-blind safety trials. If third-party placebo-controlled double-blind clinical data demonstrates that the product is not safe, the prohibition in subparagraph (B) of paragraph (19) of subdivision (b) shall apply.
CORRECTIONS: HeadingLine 1.|
Date
|
Status
|
|---|---|
| Oct 1, 2025 | Chaptered by Secretary of State. Chapter 208, Statutes of 2025. |
| Oct 1, 2025 | Approved by the Governor. |
| Sep 22, 2025 | Enrolled and presented to the Governor at 11 a.m. |
| Sep 11, 2025 | Assembly amendments concurred in. (Ayes 40. Noes 0. Page 2901.) Ordered to engrossing and enrolling. |
| Sep 8, 2025 | In Senate. Concurrence in Assembly amendments pending. |
| Sep 8, 2025 | Read third time. Urgency clause adopted. Passed. (Ayes 78. Noes 0. Page 2980.) Ordered to the Senate. |
| Sep 2, 2025 | Ordered to third reading. |
| Sep 2, 2025 | Read third time and amended. |
| Aug 18, 2025 | Ordered to third reading. |
| Aug 18, 2025 | Action rescinded whereby bill was read a third time, urgency clause adopted, passed, and ordered to the Senate. |
| Jul 17, 2025 | In Assembly. Held at Desk. |
| Jul 17, 2025 | Ordered to the Assembly. |
| Jun 27, 2025 | In Senate. Concurrence in Assembly amendments pending. |
| Jun 27, 2025 | Read third time. Urgency clause adopted. Passed. (Ayes 75. Noes 0. Page 2341.) Ordered to the Senate. |
| Jun 19, 2025 | Read second time. Ordered to consent calendar. |
| Jun 18, 2025 | From committee: Do pass. Ordered to consent calendar. (Ayes 7. Noes 0.) (June 17). |
| Jun 12, 2025 | From committee with author's amendments. Read second time and amended. Re-referred to Com. on E.S & T.M. |
| May 8, 2025 | From committee with author's amendments. Read second time and amended. Re-referred to Com. on E.S & T.M. |
| Apr 28, 2025 | Referred to Com. on E.S & T.M. |
| Mar 28, 2025 | In Assembly. Read first time. Held at Desk. |
| Mar 28, 2025 | Read third time. Urgency clause adopted. Passed. (Ayes 34. Noes 0. Page 584.) Ordered to the Assembly. |
| Mar 20, 2025 | Read second time. Ordered to consent calendar. |
| Mar 19, 2025 | From committee: Do pass. Ordered to consent calendar. (Ayes 8. Noes 0. Page 421.) (March 19). |
| Mar 3, 2025 | Set for hearing March 19. |
| Feb 27, 2025 | March 5 hearing postponed by committee. |
| Feb 25, 2025 | Set for hearing March 5. |
| Feb 11, 2025 | From committee with author's amendments. Read second time and amended. Re-referred to Com. on E.Q. |
| Jan 29, 2025 | Referred to Com. on E.Q. |
| Jan 6, 2025 | Read first time. |
| Dec 4, 2024 | (Corrected January 2). |
| Dec 4, 2024 | From printer. May be acted upon on or after January 3. |
| Dec 3, 2024 | Introduced. To Com. on RLS. for assignment. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Sep 11, 2025 | Unfinished Business SB39 Weber Pierson Urgency Clause Concurrence | Senate Floor |
Passed |
|
| Sep 8, 2025 | SB 39 Weber Pierson Third Reading Urgency By Irwin | Assembly Floor |
Passed |
|
| Jun 27, 2025 | SB 39 Weber Pierson Consent Calendar Second Day Regular Session | Assembly Floor |
Passed |
|
| Jun 17, 2025 | Do pass. To Consent Calendar. | Assembly Standing Committee on Environmental Safety and Toxic Materials |
Passed |
|
| Mar 28, 2025 | Consent Calendar 2nd SB39 Weber Pierson Urgency Clause | Senate Floor |
Passed |
|
| Mar 19, 2025 | Do pass and be ordered to the Consent Calendar | Senate Standing Committee on Environmental Quality |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
|
Organization
|
Position
|
Date
|
|---|---|---|
| American Congress Of Obstetricians & Gynecologists - District Ix | ** Support | |
| California Pan-Ethnic Health Network | ** Support | |
| Nutrablast | ** Support | |
| Ph-d Feminine Health, LLC | ** Support | |
| The Flex Company | ** Support |
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | SB 39 |
UNFINISHED BUSINESS
Bill No: SB 39
Author: Weber Pierson (D)
Amended: 9/2/25
Vote: 27 - Urgency
SENATE ENVIRONMENTAL QUALITY COMMITTEE: 8-0, 3/19/25
AYES: Blakespear, Valladares, Dahle, Gonzalez, Hurtado, Menjivar, Padilla, Pérez
SENATE FLOOR: 34-0, 3/28/25 (Consent)
AYES: Allen, Archuleta, Arreguín, Ashby, Blakespear, Cabaldon, Caballero, Cervantes, Choi, Cortese, Dahle, Durazo, Gonzalez, Grayson, Grove, Laird, Limón, McGuire, McNerney, Menjivar, Niello, Ochoa Bogh, Padilla, Pérez, Richardson, Rubio, Seyarto, Smallwood-Cuevas, Stern, Strickland, Umberg, Valladares, Wahab, Wiener
NO VOTE RECORDED: Alvarado-Gil, Becker, Hurtado, Jones, Reyes, Weber Pierson
ASSEMBLY FLOOR: 78-0, 9/8/25 - See last page for vote
SUBJECT: Cosmetic safety: vaginal suppositories
SOURCE: Author
DIGEST:
This bill exempts boric acid vaginal suppositories (BAS) from a prohibition on boric acid, and requires BAS to include a product label commencing January 1, 2027, and bans BAS commencing January 1, 2035, unless the BAS product becomes regulated by the federal Food and Drug Administration.
Assembly Amendments
require boric acid vaginal suppositories (BAS) to include a product label commencing January 1, 2027, and ban BAS commencing January 1, 2035, unless the BAS product becomes regulated as a drug by the United States Food and Drug Administration, and address a chaptering conflict to restrict and prohibit the manufacture, sale, delivery, hold, or offering for sale cosmetic products that contain any of the specified musk-related ingredients, beginning January 1, 2027.
ANALYSIS:
Existing federal law requires, pursuant to the federal Food, Drug & Cosmetic Act (FD&C Act), cosmetics produced or distributed for retail sale to consumers for their personal care to bear an ingredient declaration. (21 Code of Federal Regulations 701.3)
Existing state law:
- Defines, pursuant to the Sherman Act, “cosmetic” as any article, or its components, intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to, the human body, or any part of the human body, for cleansing, beautifying, promoting attractiveness, or altering the appearance. Further, the law makes it unlawful for any person to manufacture, sell, deliver, hold, or offer for sale any cosmetic that is adulterated or for any person to adulterate any cosmetic. (Health & Safety Code (HSC) § 109900)
- Requires, pursuant to the Safe Consumer Cosmetic Act (Cosmetics Act), a manufacturer of a cosmetic that is subject to regulation by the federal Food and Drug Administration (FDA) to submit to the California Department of Public Health (CDPH) a list of its cosmetic products sold in California that contain any ingredient that is a chemical identified as causing cancer or reproductive toxicity. (HSC § 111792)
- Requires the Department of Toxic Substances Control (DTSC), under the state's Green Chemistry regulations, to establish a process to identify and prioritize chemicals or chemical ingredients in consumer products that may be considered a chemical of concern. (HSC § 25252)
- Requires DTSC to develop and maintain a list of Candidate Chemicals that exhibit a hazard trait and/or an environmental or toxicological endpoint and is either 1) found on one or more of the statutorily specified authoritative lists or 2) is listed by DTSC using specified criteria. (California Code of Regulations § 69502.2 (b))
- Prohibits a person or entity from manufacturing, selling, delivering, holding, or offering for sale in commerce any cosmetic product that contains 24 specified intentionally added chemical ingredients commencing January 1, 2025. Further, prohibits a person or entity from manufacturing, selling, delivering, holding, or offering for sale in commerce any cosmetic product that contains 41 specified intentionally added chemical ingredients commencing January 1, 2027. (HSC § 108980)
This bill:
- Exempts a BAS product from the prohibitions of manufacturing, selling, delivering, holding, or offering for sale in commerce any cosmetic product containing the intentionally added ingredients specified in subparagraph (B) of paragraph (19) of subdivision (b) of Section 108980 of the Health and Safety Code (boric acid) under specified conditions.
- Requires a person or entity that manufactures, sells, delivers, holds, or offers for sale in commerce a BAS product that is not regulated as a drug by the FDA to include a warning statement on the product label commencing January 1, 2027.
- Prohibits the manufacture, sale, delivery, hold, or offering for sale in commerce of a BAS product that is not regulated as a drug by the FDA commencing January 1, 2035.
- Makes related findings and declarations.
- Addresses a chaptering conflict by joining in AB 60 (Papan), which restricts and prohibits the manufacture, sale, delivery, hold, or offering for sale cosmetic products that contain any of the specified musk-related ingredients, beginning January 1, 2027.
Background
- Regulatory requirements for California’s cosmetics. Prior to 2020, California had two laws governing the safety of cosmetics: The Sherman Act and the Cosmetics Act. These laws focused on the identification and notification of hazardous chemicals in cosmetics and outlawing the tampering of products. The Sherman Act prohibits the manufacture, sale, delivery, hold, or offer for sale of any cosmetic that is adulterated and makes it unlawful for any person to adulterate any cosmetic. The Cosmetic Act, established by SB 484 (Migden, Chapter 729, Statutes of 2005), requires the manufacturer, packer, and/or distributor of cosmetic products to provide the CDPH a list of all cosmetic products that contain any ingredient known or suspected to cause cancer, birth defects, or other reproductive harm. CDPH does not have any enforcement authority over the manufacturers that are covered, so compliance may be lacking.
- Chemical bans for cosmetics. Over the past several years, California has shifted its approach to the regulation of cosmetics. Section 108980 of the Health and Safety Code, as established by AB 496 (Friedman, Chapter 441, Statutes of 2023) and AB 2762 (Muratsuchi, Chapter 314, Statutes of 2020), prohibits the manufacture, sale, delivery, holding, or offering for sale in commerce any cosmetic product that contains any of 65 intentionally added ingredients. This approach is meant to reflect the hazard-based, regulatory framework of the European Union (EU) and leads to the banning of hazardous chemicals in cosmetics. On September 15, 2022, the European Commission published Regulation (EU) 2022/1531 to amend Cosmetics Regulation (EC) No. 1223/2009 for the use of certain ingredients classified as carcinogenic, mutagenic, or toxic for reproduction (CMR substances) in cosmetic products.
These regulations require EU member states to prohibit the marketing of cosmetic products containing these ingredients. The scope of products covered under the EU's definition of cosmetics is broader than the scope of products covered under California's definition of cosmetics.
- The use of boric acid in suppositories. Boric acid is a naturally occurring chemical that is associated with antifungal activity and can quickly kill 50-90% of certain fungi.[1] Boric acid suppositories (BAS) are gelatin capsules of boric acid applied intravaginally and said to address vaginal odor and infections, such as yeast infections and bacterial vaginosis. BAS are marketed as a natural remedy and an alternative to pharmaceuticals. They are sometimes encouraged for use when other viable treatment options have been exhausted and for stubborn and recurrent infections.[2] Boric acid is recommended for use against atypical species of fungi and more severe infections.[3] Only 5-10% of yeast infections are caused by atypical species.3 The Centers for Disease Control and Prevention (CDC) and the American College of Obstetricians and Gynecologists (ACOG) recommend the use of boric acid in a gelatin capsule only after recurrence of a yeast infection caused by atypical fungi species and after longer periods of treatment via other methods.3,[4] BAS are considered to be effective as experimental results have demonstrated that these products can lead to relief from symptoms of vaginal infections within 48 hours.[5]
Though useful in suppositories, boric acid has been considered reproductively toxic over the last 50 years.[6] Boric acid was added to the List of Substances Prohibited in Cosmetic Products (Annex II) in the EU in 2022. There, it is classified as a reproductive toxicant and BAS is currently not available for purchase in the EU. Boric acid is also identified as a Candidate Chemical for the California Department of Toxic Substances Control (DTSC). The Expert Panel for Cosmetic Ingredient Safety concluded that boric acid in concentrations less than or equal to 5% is safe.5 The capsules of BAS typically contain 0.6 grams of boric acid and are considered safe for use as 15 grams of boric acid can have toxic effects.[7],[8] Because BAS are administered intravaginally, the risk of introducing the toxic chemical to other parts of the body is lower, however, there is a risk of introducing the toxic chemical into the bloodstream if there is damage to the vaginal wall.1,5 There are side effects of BAS including increased irritation, burning, and vaginal discharge.
Boric acid use is not recommended for pregnant women, as there is limited data on its harmful effects. Experts recommend that affected individuals consult their healthcare provider before using BAS to treat infections. Researchers claim that BAS should not be considered for the first-line treatment of uncomplicated vaginal infections because of insufficient data, controversy surrounding safety, and the availability of safer and effective treatments.1 Because of its potential ability to impair fertility, researchers also suggest boric acid be considered a last option in exceptional cases for non-pregnant women.[9],[10] The alternatives to BAS include prescribed antifungal and antibacterial medication, probiotics, and diets incorporating fermented food.
- A controversial capsule. BAS are currently not approved by the U.S. Food and Drug Administration (FDA) and have not been rigorously tested to ensure that they are safe and effective for use. Their status with the FDA classifies BAS as homeopathic products, which are not required to be reviewed by the FDA. Homeopathic products tend to pose higher risks to public health because they may contain unsafe ingredients, undergo improper and unregulated manufacturing, have contamination, and lack labels that inform consumers of risks and side effects. BAS also tend to be marketed to treat and prevent infections, which could qualify these products as drugs. Under the Federal Food, Drug, and Cosmetic Act, products marketed in this manner and without FDA approval would violate federal law. In 2018, the FDA issued a warning to a manufacturer of a BAS product sold by the sponsor of this bill (pH-D Feminine Health) claiming that the online marketing of their product characterized their product as a drug. This was based on the manner in which the product is administered and the ailments it addresses. The manufacturer argued that the product has long been considered a cosmetic and should be regulated as such. The sponsor also alleges that they were advised incorrectly on acceptable marketing. As a result, the FDA required the product to undergo clinical trials and the manufacturer began to market the product as a cosmetic that solely addresses vaginal odor.
In 2024, a class action lawsuit was filed against manufacturers for illegally selling BAS marketed to treat and prevent infections without FDA approval. Additionally in 2024, Women’s Voices for the Earth, on behalf of several health and advocacy organizations, issued a letter of concern to a healthcare manufacturer to remove boric acid from their intimate care products over concerns of reproductive safety and to stop the spread of misinformation. This class action lawsuit is still pending.
Comments
- Purpose of this bill. According to the author, “SB 39 will allow boric acid to continue to be used in vaginal and vulvar products sold in the State of California, and ultimately nationwide, as national retailers do not sell state-specific products. These products are marketed as cosmetics and are used by healthcare providers to treat two of the most common issues affecting women: vaginal yeast infections and vaginal odor. There is robust safety and efficacy data on the use of boric acid products in vaginal and vulvar products. For example, the Centers for Disease Control and Prevention (CDC) recommends the use of boric acid suppositories (BAS) in their current STD guidelines (published 2015). Likewise, The American College of Obstetrics and Gynecology (ACOG) recommends the use of boric acid suppositories (BAS) in vaginal health applications. Boric acid products are readily available at every major retailer in the US. Healthcare providers guide their patients to purchase boric acid products at these retailers. Data shows that in areas where healthcare deserts exist, the sales of boric acid products are significantly higher, as well as healthcare providers instructing their patients to purchase these affordable products. Unless SB 39 is enacted, the ban on boric acid will prohibit women from accessing boric acid products and eliminate a woman’s right to choose how to manage her feminine health (especially in disadvantaged populations), eliminating a safe, effective, and accessible non-antibiotic treatment for conditions such as vaginal odor and yeast infections.”
- Accessibility to over-the-counter medications. Boric acid suppositories are sold over the counter and do not require a prescription from a healthcare provider. This leaves an option for affected individuals to receive treatment and relief without a visit to the doctor. This is an important consideration given that 8% of women in California do not have access to health insurance and would not be prescribed alternative treatment options.[11] If these products are unavailable to current consumers, there is also the potential for affected individuals to seek boric acid intended for other applications to make homemade suppositories, which could put these individuals at a higher risk. Some research has claimed that BAS could be a safe and economic option for women with recurrent and chronic symptoms of vaginitis when conventional treatment fails with atypical, resistant strains of fungi.2,[12] However, given that there are concerns surrounding the hazardous nature of boric acid, insufficient data on safety, and that it is listed as a reproductive toxicant on the EU's List of Substances Prohibited in Cosmetic Products and the Candidate Chemical list for DTSC, more transparency could protect consumers and allow them to make an informed choice regarding the substances they introduce into their bodies. The temporary warning labeling requirement will provide such transparency for those who will continue to use BAS products until they are regulated by the FDA.
Related/Prior Legislation
AB 496 (Friedman, Chapter 441, Statutes of 2023) prohibits, beginning January 1, 2027, the manufacture, sale, delivery, holding, or offering for sale in commerce of any cosmetic product containing 41 specified intentionally added ingredients.
AB 2771 (Friedman, Chapter 804, Statutes of 2022) prohibits any person or entity from manufacturing, selling, delivering, holding, or offering for sale in commerce any cosmetic product that contains any per- or polyfluoroalkyl substance (PFAS).
AB 2762 (Muratsuchi, Chapter 314, Statutes of 2020) prohibits, beginning January 1, 2025, the manufacture, sale, delivery, holding, or offering for sale in commerce of any cosmetic product containing 24 specified intentionally added ingredients.
FISCAL EFFECT: Appropriation: No Fiscal Com.: No Local: No
SUPPORT: (Verified 9/8/25)
American Congress of Obstetricians & Gynecologists - District Ix
Nutrablast
Ph-d Feminine Health, LLC
The Flex Company
OPPOSITION: (Verified 9/8/25)
None received
ASSEMBLY FLOOR: 78-0, 9/8/25
AYES: Addis, Aguiar-Curry, Ahrens, Alanis, Alvarez, Arambula, Ávila Farías, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Caloza, Carrillo, Castillo, Chen, Connolly, Davies, DeMaio, Dixon, Elhawary, Ellis, Flora, Fong, Gabriel, Gallagher, Garcia, Gipson, Jeff Gonzalez, Mark González, Hadwick, Haney, Harabedian, Hart, Hoover, Irwin, Jackson, Johnson, Kalra, Krell, Lackey, Lee, Lowenthal, Macedo, McKinnor, Ortega, Pacheco, Papan, Patel, Patterson, Pellerin, Petrie-Norris, Quirk-Silva, Ramos, Ransom, Celeste Rodriguez, Michelle Rodriguez, Rogers, Blanca Rubio, Sanchez, Schiavo, Schultz, Sharp-Collins, Solache, Soria, Stefani, Ta, Tangipa, Valencia, Wallis, Ward, Wicks, Wilson, Zbur, Rivas
NO VOTE RECORDED: Muratsuchi, Nguyen
ASSEMBLY FLOOR: 75-0, 6/27/25
AYES: Addis, Aguiar-Curry, Ahrens, Alanis, Alvarez, Arambula, Ávila Farías, Bains, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Caloza, Carrillo, Castillo, Chen, Connolly, Davies, DeMaio, Dixon, Elhawary, Ellis, Fong, Gabriel, Gallagher, Garcia, Gipson, Jeff Gonzalez, Mark González, Hadwick, Haney, Harabedian, Hart, Hoover, Irwin, Jackson, Kalra, Krell, Lackey, Lee, Lowenthal, Macedo, McKinnor, Muratsuchi, Nguyen, Ortega, Pacheco, Papan, Patel, Patterson, Petrie-Norris, Quirk-Silva, Ramos, Ransom, Celeste Rodriguez, Michelle Rodriguez, Rogers, Sanchez, Schiavo, Schultz, Sharp-Collins, Solache, Soria, Stefani, Ta, Tangipa, Valencia, Wallis, Ward, Wicks, Wilson, Zbur, Rivas
NO VOTE RECORDED: Bauer-Kahan, Flora, Pellerin, Blanca Rubio
Prepared by: Taylor McKie / E.Q. / (916) 651-4108
9/8/25 19:32:05
**** END ****
Prutting, S. M., & Cerveny, J. D. (1998). Boric acid vaginal suppositories: a brief review. Infectious diseases in obstetrics and gynecology, 6(4), 191. ↑
Iavazzo, C., Gkegkes, I. D., Zarkada, I. M., & Falagas, M. E. (2011). Boric acid for recurrent vulvovaginal candidiasis: the clinical evidence. Journal of women's health, 20(8), 1245-1255. ↑
Paavonen, J. A., & Brunham, R. C. (2020). Vaginitis in nonpregnant patients: ACOG practice bulletin number 215. Obstetrics & Gynecology, 135(5), 1229-1230. ↑
Centers for Disease Control and Prevention. (2021). Vulvovaginal Candidiasis. www.cdc.gov/std/treatment-guidelines/candidiasis.htm#print ↑
Writer, C. I. R. (2024). Safety Assessment of Boric Acid and Sodium Borate as Used in Cosmetics. ↑
Chapin, R. E., & Ku, W. W. (1994). The reproductive toxicity of boric acid. Environmental health perspectives, 102(suppl 7), 87-91. ↑
Farfán-García, E. D., Castillo-Mendieta, N. T., Ciprés-Flores, F. J., Padilla-Martínez, I. I., Trujillo-Ferrara, J. G., & Soriano-Ursúa, M. A. (2016). Current data regarding the structure-toxicity relationship of boron-containing compounds. Toxicology letters, 258, 115-125. ↑
Sevim, Ç., & Kara, M. (2022). Boron and boron-containing compounds toxicity. In The Toxicity of Environmental Pollutants. IntechOpen. ↑
Donders, G., Sziller, I. O., Paavonen, J., Hay, P., de Seta, F., Bohbot, J. M., ... & Mendling, W. (2022). Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion. Frontiers in Cellular and Infection Microbiology, 12, 934353. ↑
Farr, A., Effendy, I., Frey Tirri, B., Hof, H., Mayser, P., Petricevic, L., ... & Mendling, W. (2021). Guideline: vulvovaginal candidosis (AWMF 015/072, level S2k). Mycoses, 64(6), 583-602. ↑
KFF (2023). California Women’s Health Insurance Coverage Data ↑
Mittelstaedt, R., Kretz, A., Levine, M., Handa, V. L., Ghanem, K. G., Sobel, J. D., ... & Tuddenham, S. (2021). Data on safety of intravaginal boric acid use in pregnant and nonpregnant women: a narrative review. Sexually transmitted diseases, 48(12), e241-e247. ↑
SENATE THIRD READING
STR Bill Id:SB 39
Author:(Weber Pierson)
As Amended Ver:September 02, 2025
2/3 vote. Urgency
SUMMARY
Requires, commencing on January 1, 2027, a person or entity that manufactures or sells a vaginal boric acid suppository (BAS) product to include specified language on the product label; prohibits, beginning on January 1, 2035, a person or entity from manufacturing or selling a BAS product; provides that neither of these provisions apply if a BAS product becomes regulated as a drug under the United States Food and Drug Administration (FDA).
Major Provisions
- Makes several findings and declarations.
- Requires, commencing on January 1, 2027, a person or entity that manufactures, sells, delivers, holds, or offers for sale in commerce a vaginal suppository product containing intentionally added boric acid to include on the product label a warning statement, as specified.
- Prohibits, commencing on January 1, 2035, a person or entity from manufacturing, selling, delivering, holding, or offering for sale in commerce a vaginal suppository product containing intentionally added boric acid.
- Provides that the above labeling requirement and prohibition do not apply to a vaginal suppository product containing intentionally added boric acid, if the product becomes regulated as a drug by the FDA.
- Defines "product label" to mean a display of written, printed, or graphic matter upon a cosmetic product or upon its immediate container.
- Provides that this bill is an urgency statute necessary for the immediate preservation of the public peace, health, or safety within the meaning of the California Constitution and shall go into immediate effect, in order for women in this state to have necessary medical and hygiene materials available to them in a timely manner.
- Adds provisions from AB 60 (Papan, 2025) to resolve a chaptering conflict; provides that these provisions shall only become operative if both AB 60 and SB 39 are enacted.
COMMENTS
Boric acid, BAS, and vaginal infections: Boric acid is a naturally-occurring compound with antimicrobial properties. Due to its potential to cause reproductive harm, the European Union bans the use of boric acid in cosmetic products, and California's Department of Toxic Substances Control (DTSC) lists boric acid as a "candidate chemical" under its Safer Consumer Products program, which aims to advance the design, development, and use of products that are chemically safer for people and the environment. Candidate chemicals have known hazard traits and/or environmental or toxicological risks, and DTSC uses its Candidate Chemicals list to identify potential product-chemical combinations for future regulation.
Despite its potential for toxicity, boric acid is sometimes used in healthcare applications due to its antimicrobial properties. BAS are gelatin capsules containing boric acid, applied intravaginally to treat vaginal infections caused by yeast or bacteria, or to address vaginal odor (although some medical organizations, such as the Cleveland Clinic, state that vaginal odor is common and generally does not require treatment, except when the odor is strong and unfamiliar or unpleasant, which can signal a potential infection and is often accompanied by other symptoms).
BAS are easily available over-the-counter and, although they are often used to address vaginal infections, they are not currently regulated as drugs under the FDA. In 2021, researchers from the Johns Hopkins School of Medicine published the study, "Data on safety of intravaginal boric acid use in pregnant and non-pregnant women: A narrative review," in the journal Sexually Transmitted Diseases. The authors note that safety data specific to intravaginal boric acid use are sparse; however, the authors also note that intravaginal boric acid represents one of the only options available to treat recurrent vaginal infections caused by certain strains of drug resistant fungal and bacterial microbes. Guidelines from several medical professional and public health organizations, including the American College of Obstetricians and Gynecologists, advise that intravaginal boric acid use should be avoided in pregnancy.
Federal regulation of cosmetics versus drugs: At the federal level, the federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes the FDA to oversee and regulate the production, sale, and distribution of food, drugs, medical devices, and cosmetics. Under the FD&C, a cosmetic is defined as an article "intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to the human body or any part thereof for cleansing, beautifying, promoting attractiveness, or altering the appearance," as well as any substance intended for use as a component in a cosmetic product. Products intended for a therapeutic use, such as treating or preventing disease, or to affect the structure or function of the body, are considered drugs under the FD&C.
In some ways, the FDA's authority to regulate cosmetics is more limited than its authority to regulate drugs. Unlike drugs, cosmetic products and ingredients do not need FDA premarket approval, with the exception of color additives. In addition, for the most part, a manufacturer may use any ingredient in the formulation of a cosmetic, provided that the ingredient and the finished cosmetic are "safe under labeled or customary conditions of use," the product is properly labeled, and use of the ingredient does not cause the cosmetic to be adulterated or misbranded under the FD&C. Neither the law nor regulations require specific tests to demonstrate the safety of individual cosmetic products or ingredients.
State regulation of cosmetics: Before January 2021, California's primary law for governing the safety of cosmetics was the state's Sherman Food, Drug, and Cosmetic Law (Sherman Law). The Sherman Law (Health and Safety Code (HSC) § 109875, et seq.) is administered by the California Department of Public Health (CDPH) and serves as California's state level, implementing legislation for the federal FD&C. Under the Sherman Law, selling misbranded cosmetics can lead to civil and administrative penalties, embargoes, and even bans on products.
In addition, the California Safe Cosmetics Act of 2005 (Cosmetics Act; HSC § 111791, et seq.), housed under Sherman Law, requires manufacturers of any cosmetic product, sold into California and subject to regulation by the FDA, to provide CDPH with a complete and accurate list of cosmetic products that contain any ingredient that is a carcinogen or reproductive toxicant. The Cosmetics Act further requires CDPH to maintain a consumer-friendly, searchable online database that contains product information collected by CDPH pursuant to the Cosmetics Act.
In 2020, AB 2762 (Muratsuchi, Chapter 314) was signed into law, establishing a new body of statute that, independent of the state's Sherman Law, prohibits the manufacture or sale of cosmetic products containing any one of 24 chemicals as intentionally added ingredients. In 2023, AB 496 (Friedman, Chapter 441) added another 41 chemicals, including boric acid, to the list. For both bills, the aim was to prohibit chemicals in California that had already been banned from cosmetics in the European Union, due to their classification as substances with carcinogenic, mutagenic (i.e., capable of causing genetic mutations), or reproductive toxicity properties. This bill would provide manufacturers of BAS, which contain intentionally added boric acid, with an additional eight years before the prohibition takes effect, to allow them time to undergo the FDA's drug development and review process and become regulated as drugs under the FD&C.
FDA action on BAS: When the FDA identifies what it believes are significant violations of federal requirements, it notifies the appropriate party, often through a "warning letter." In August 2018, the FDA issued a warning letter to Vireo Resources regarding its product, pH-D Feminine Health Support Boric Acid Vaginal Suppositories. In the letter, in a section entitled "Unapproved New Drug and Misbranded Drug," the FDA states:
"Statements on your website…establish that pH-D Feminine Health Support Boric Acid Vaginal Suppositories is a drug as defined [under the FD&C], because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or to affect the structure or function of the body…New drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from the FDA…No approved application pursuant to section 505 of the Act [21 U.S.C. § 355] is in effect for this product…
Your pH-D Feminine Health Support Boric Acid Vaginal Suppositories is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, adequate directions for use cannot be written so that a layperson can use your product safely for its intended purposes. Accordingly, pH-D Feminine Health Support Boric Acid Vaginal Suppositories fails to bear adequate directions for its intended uses and, therefore, the product is misbranded under [the FD&C]."
Multi-year drug development and review process under the FDA: At the time of the writing of this analysis, some manufacturers are in the process of pursuing FDA drug approval for their BAS products. The FDA's drug development and review process can take a number of years to complete and includes numerous steps. According to the FDA, the clinical trials stage often takes the longest time, usually multiple years. If a drug receives FDA approval, it then becomes subject to FDA regulatory oversight, in which the FDA monitors real-time data from patients, drug manufacturers, and healthcare professionals, including reports of adverse reactions. Based on these data, the FDA can take various actions, including updating drug labeling requirements to ensure safe use, and issuing drug recalls.
This bill: Current state law bans the manufacture and sale of cosmetic products containing intentionally added boric acid, beginning on January 1, 2027. Because BAS represents one of the few options available to treat recurrent vaginal infections caused by drug resistant microbes, SB 39 provides manufacturers of BAS products with an additional eight years before they are banned under state law, to provide them with time to undergo the FDA's drug development and review process and pursue status and regulation as an FDA-approved drug. Further, the bill provides that BAS products that become regulated under the FDA as a drug would not be subject to the ban on cosmetics containing intentionally added boric acid. To provide a layer of consumer protection while manufacturers pursue regulation of their BAS products as drugs under the FDA, this bill further requires that manufacturers label their products with information pertaining to the safe use of BAS, including that these products should not be used during pregnancy, or while nursing or trying to conceive. Overall, SB 39 takes a targeted approach to preserving people's ability to access BAS products, without weakening state laws aimed at protecting consumers from cosmetics containing chemicals with known carcinogenic, mutagenic, and reproductive toxicity traits.
According to the Author
"There is robust safety and efficacy data on the use of boric acid in vaginal products, so much so that they have been standard of care in women’s health for many years. For example, the Centers for Disease Control and Prevention (CDC) recommends the use of boric acid suppositories (BAS) in their current [sexually transmitted disease] guidelines (published 2015). Likewise, the American College of Obstetricians and Gynecologists (ACOG) recommends the use of BAS in vaginal health applications. Additionally, BAS are on the treatment protocols of many major academic and medical centers and/or are recommended for their patients (e.g., Kaiser Permanente, UCLA, Harvard, Columbia, Tufts, and American Association of Family Physicians).
Boric acid products are readily available at every major retailer in the US and are also available on Amazon. Healthcare providers guide their patients to purchase boric acid products at these retailers. Unless SB 39 is enacted, the ban on boric acid will prohibit women from accessing boric acid products and eliminate a woman’s right to choose how to manage her feminine health (especially in disadvantaged populations), eliminating a safe, effective, and accessible non-antibiotic treatment for conditions such as vaginal odor and yeast infections."
Arguments in Support
According to the California Pan-Ethnic Health Network:
"Boric acid suppositories are a long-standing, evidence-based, effective and affordable treatment option for managing yeast infections and bacterial vaginosis—conditions that disproportionately affect low-income women of color who face systemic barriers to health care. Current regulations on cosmetic products as created by AB 2762 (Muratsuchi, Chapter 314, Statutes of 2020) and amended by AB 496 (Friedman, Chapter 441, Statutes of 2023) exclude boric acid, forcing many individuals to choose between unregulated markets or untreated infections which can lead to severe reproductive complications. SB 39 would add a necessary and thoughtful update to California’s regulations for cosmetic products and ensure access to boric acid in gynecological care."
Arguments in Opposition
None on file.
FISCAL COMMENTS
This bill is keyed non-fiscal by Legislative Counsel.
VOTES
SENATE FLOOR: 34-0-6
YES: Allen, Archuleta, Arreguín, Ashby, Blakespear, Cabaldon, Caballero, Cervantes, Choi, Cortese, Dahle, Durazo, Gonzalez, Grayson, Grove, Laird, Limón, McGuire, McNerney, Menjivar, Niello, Ochoa Bogh, Padilla, Pérez, Richardson, Rubio, Seyarto, Smallwood-Cuevas, Stern, Strickland, Umberg, Valladares, Wahab, Wiener
ABS, ABST OR NV: Alvarado-Gil, Becker, Hurtado, Jones, Reyes, Weber Pierson
ASM ENVIRONMENTAL SAFETY AND TOXIC MATERIALS: 7-0-0
YES: Connolly, Ellis, Bauer-Kahan, Castillo, Lee, McKinnor, Papan
ASSEMBLY FLOOR: 75-0-4
YES: Addis, Aguiar-Curry, Ahrens, Alanis, Alvarez, Arambula, Ávila Farías, Bains, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Caloza, Carrillo, Castillo, Chen, Connolly, Davies, DeMaio, Dixon, Elhawary, Ellis, Fong, Gabriel, Gallagher, Garcia, Gipson, Jeff Gonzalez, Mark González, Hadwick, Haney, Harabedian, Hart, Hoover, Irwin, Jackson, Kalra, Krell, Lackey, Lee, Lowenthal, Macedo, McKinnor, Muratsuchi, Nguyen, Ortega, Pacheco, Papan, Patel, Patterson, Petrie-Norris, Quirk-Silva, Ramos, Ransom, Celeste Rodriguez, Michelle Rodriguez, Rogers, Sanchez, Schiavo, Schultz, Sharp-Collins, Solache, Soria, Stefani, Ta, Tangipa, Valencia, Wallis, Ward, Wicks, Wilson, Zbur, Rivas
ABS, ABST OR NV: Bauer-Kahan, Flora, Pellerin, Blanca Rubio
UPDATED
VERSION: September 02, 2025
CONSULTANT: Naomi Ondrasek / E.S. & T.M. / (916) 319-3965 FN: 0001495
SENATE THIRD READING
STR Bill Id:SB 39
Author:(Weber Pierson)
As Amended Ver:June 12, 2025
2/3 vote. Urgency
SUMMARY
Requires, commencing on January 1, 2027, a person or entity that manufactures or sells a vaginal boric acid suppository (BAS) product to include specified language on the product label; prohibits, beginning on January 1, 2035, a person or entity from manufacturing or selling a BAS product; provides that neither of these provisions apply if a BAS product becomes regulated as a drug under the United States Food and Drug Administration (FDA).
Major Provisions
- Makes several findings and declarations.
- Requires, commencing on January 1, 2027, a person or entity that manufactures, sells, delivers, holds, or offers for sale in commerce a vaginal suppository product containing intentionally added boric acid to include on the product label a warning statement, as specified.
- Prohibits, commencing on January 1, 2035, a person or entity from manufacturing, selling, delivering, holding, or offering for sale in commerce a vaginal suppository product containing intentionally added boric acid.
- Provides that the above labeling requirement and prohibition do not apply to a vaginal suppository product containing intentionally added boric acid, if the product becomes regulated as a drug by the FDA.
- Defines "product label" to mean a display of written, printed, or graphic matter upon a cosmetic product or upon its immediate container.
- Provides that this bill is an urgency statute necessary for the immediate preservation of the public peace, health, or safety within the meaning of the California Constitution and shall go into immediate effect, in order for women in this state to have necessary medical and hygiene materials available to them in a timely manner.
COMMENTS
Boric acid, BAS, and vaginal infections: Boric acid is a naturally-occurring compound with antimicrobial properties. Due to its potential to cause reproductive harm, the European Union bans the use of boric acid in cosmetic products, and California's Department of Toxic Substances Control (DTSC) lists boric acid as a "candidate chemical" under its Safer Consumer Products program, which aims to advance the design, development, and use of products that are chemically safer for people and the environment. Candidate chemicals have known hazard traits and/or environmental or toxicological risks, and DTSC uses its Candidate Chemicals list to identify potential product-chemical combinations for future regulation.
Despite its potential for toxicity, boric acid is sometimes used in healthcare applications due to its antimicrobial properties. BAS are gelatin capsules containing boric acid, applied intravaginally to treat vaginal infections caused by yeast or bacteria, or to address vaginal odor (although some medical organizations, such as the Cleveland Clinic, state that vaginal odor is common and generally does not require treatment, except when the odor is strong and unfamiliar or unpleasant, which can signal a potential infection and is often accompanied by other symptoms).
BAS are easily available over-the-counter and, although they are often used to address vaginal infections, they are not currently regulated as drugs under the FDA. In 2021, researchers from the Johns Hopkins School of Medicine published the study, "Data on safety of intravaginal boric acid use in pregnant and non-pregnant women: A narrative review," in the journal Sexually Transmitted Diseases. The authors note that safety data specific to intravaginal boric acid use are sparse; however, the authors also note that intravaginal boric acid represents one of the only options available to treat recurrent vaginal infections caused by certain strains of drug resistant fungal and bacterial microbes. Guidelines from several medical professional and public health organizations, including the American College of Obstetricians and Gynecologists, advise that intravaginal boric acid use should be avoided in pregnancy.
Federal regulation of cosmetics versus drugs: At the federal level, the federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes the FDA to oversee and regulate the production, sale, and distribution of food, drugs, medical devices, and cosmetics. Under the FD&C, a cosmetic is defined as an article "intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to the human body or any part thereof for cleansing, beautifying, promoting attractiveness, or altering the appearance," as well as any substance intended for use as a component in a cosmetic product. Products intended for a therapeutic use, such as treating or preventing disease, or to affect the structure or function of the body, are considered drugs under the FD&C.
In some ways, the FDA's authority to regulate cosmetics is more limited than its authority to regulate drugs. Unlike drugs, cosmetic products and ingredients do not need FDA premarket approval, with the exception of color additives. In addition, for the most part, a manufacturer may use any ingredient in the formulation of a cosmetic, provided that the ingredient and the finished cosmetic are "safe under labeled or customary conditions of use," the product is properly labeled, and use of the ingredient does not cause the cosmetic to be adulterated or misbranded under the FD&C. Neither the law nor regulations require specific tests to demonstrate the safety of individual cosmetic products or ingredients.
State regulation of cosmetics: Before January 2021, California's primary law for governing the safety of cosmetics was the state's Sherman Food, Drug, and Cosmetic Law (Sherman Law). The Sherman Law (Health and Safety Code (HSC) Section 109875, et seq.) is administered by the California Department of Public Health (CDPH) and serves as California's state level, implementing legislation for the federal FD&C. Under the Sherman Law, selling misbranded cosmetics can lead to civil and administrative penalties, embargoes, and even bans on products.
In addition, the California Safe Cosmetics Act of 2005 (Cosmetics Act; HSC Section 111791, et seq.), housed under Sherman Law, requires manufacturers of any cosmetic product, sold into California and subject to regulation by the FDA, to provide CDPH with a complete and accurate list of cosmetic products that contain any ingredient that is a carcinogen or reproductive toxicant. The Cosmetics Act further requires CDPH to maintain a consumer-friendly, searchable online database that contains product information collected by CDPH pursuant to the Cosmetics Act.
In 2020, AB 2762 (Muratsuchi, Chapter 314) was signed into law, establishing a new body of statute that, independent of the state's Sherman Law, prohibits the manufacture or sale of cosmetic products containing any one of 24 chemicals as intentionally added ingredients. In 2023, AB 496 (Friedman, Chapter 441) added another 41 chemicals, including boric acid, to the list. For both bills, the aim was to prohibit chemicals in California that had already been banned from cosmetics in the European Union, due to their classification as substances with carcinogenic, mutagenic (i.e., capable of causing genetic mutations), or reproductive toxicity properties. This bill would provide manufacturers of BAS, which contain intentionally added boric acid, with an additional eight years before the prohibition takes effect, to allow them time to undergo the FDA's drug development and review process and become regulated as drugs under the FD&C.
FDA action on BAS: When the FDA identifies what it believes are significant violations of federal requirements, it notifies the appropriate party, often through a "warning letter." In August 2018, the FDA issued a warning letter to Vireo Resources regarding its product, pH-D Feminine Health Support Boric Acid Vaginal Suppositories. In the letter, in a section entitled "Unapproved New Drug and Misbranded Drug," the FDA states:
"Statements on your website…establish that pH-D Feminine Health Support Boric Acid Vaginal Suppositories is a drug as defined [under the FD&C], because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or to affect the structure or function of the body…New drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from the FDA…No approved application pursuant to section 505 of the Act [21 U.S.C. Section 355] is in effect for this product…
Your pH-D Feminine Health Support Boric Acid Vaginal Suppositories is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, adequate directions for use cannot be written so that a layperson can use your product safely for its intended purposes. Accordingly, pH-D Feminine Health Support Boric Acid Vaginal Suppositories fails to bear adequate directions for its intended uses and, therefore, the product is misbranded under [the FD&C]."
Multi-year drug development and review process under the FDA: At the time of the writing of this analysis, some manufacturers are in the process of pursuing FDA drug approval for their BAS products. The FDA's drug development and review process can take a number of years to complete and includes numerous steps. According to the FDA, the clinical trials stage often takes the longest time, usually multiple years. If a drug receives FDA approval, it then becomes subject to FDA regulatory oversight, in which the FDA monitors real-time data from patients, drug manufacturers, and healthcare professionals, including reports of adverse reactions. Based on these data, the FDA can take various actions, including updating drug labeling requirements to ensure safe use, and issuing drug recalls.
This bill: Current state law bans the manufacture and sale of cosmetic products containing intentionally added boric acid, beginning on January 1, 2027. Because BAS represents one of the few options available to treat recurrent vaginal infections caused by drug resistant microbes, SB 39 provides manufacturers of BAS products with an additional eight years before they are banned under state law, to provide them with time to undergo the FDA's drug development and review process and pursue status and regulation as an FDA-approved drug. Further, the bill provides that BAS products that become regulated under the FDA as a drug would not be subject to the ban on cosmetics containing intentionally added boric acid. To provide a layer of consumer protection while manufacturers pursue regulation of their BAS products as drugs under the FDA, this bill further requires that manufacturers label their products with information pertaining to the safe use of BAS, including that these products should not be used during pregnancy, or while nursing or trying to conceive. Overall, SB 39 takes a targeted approach to preserving people's ability to access BAS products, without weakening state laws aimed at protecting consumers from cosmetics containing chemicals with known carcinogenic, mutagenic, and reproductive toxicity traits.
According to the Author
"There is robust safety and efficacy data on the use of boric acid in vaginal products, so much so that they have been standard of care in women’s health for many years. For example, the Centers for Disease Control and Prevention (CDC) recommends the use of boric acid suppositories (BAS) in their current [sexually transmitted disease] guidelines (published 2015). Likewise, the American College of Obstetricians and Gynecologists (ACOG) recommends the use of BAS in vaginal health applications. Additionally, BAS are on the treatment protocols of many major academic and medical centers and/or are recommended for their patients (e.g., Kaiser Permanente, UCLA, Harvard, Columbia, Tufts, and American Association of Family Physicians).
Boric acid products are readily available at every major retailer in the US and are also available on Amazon. Healthcare providers guide their patients to purchase boric acid products at these retailers. Unless SB 39 is enacted, the ban on boric acid will prohibit women from accessing boric acid products and eliminate a woman’s right to choose how to manage her feminine health (especially in disadvantaged populations), eliminating a safe, effective, and accessible non-antibiotic treatment for conditions such as vaginal odor and yeast infections."
Arguments in Support
According to the California Pan-Ethnic Health Network:
"Boric acid suppositories are a long-standing, evidence-based, effective and affordable treatment option for managing yeast infections and bacterial vaginosis—conditions that disproportionately affect low-income women of color who face systemic barriers to health care. Current regulations on cosmetic products as created by AB 2762 (Muratsuchi, Chapter 314, Statutes of 2020) and amended by AB 496 (Friedman, Chapter 441, Statutes of 2023) exclude boric acid, forcing many individuals to choose between unregulated markets or untreated infections which can lead to severe reproductive complications. SB 39 would add a necessary and thoughtful update to California's regulations for cosmetic products and ensure access to boric acid in gynecological care."
Arguments in Opposition
None on file.
FISCAL COMMENTS
This bill is keyed non-fiscal by Legislative Counsel.
VOTES
SENATE FLOOR: 34-0-6
YES: Allen, Archuleta, Arreguín, Ashby, Blakespear, Cabaldon, Caballero, Cervantes, Choi, Cortese, Dahle, Durazo, Gonzalez, Grayson, Grove, Laird, Limón, McGuire, McNerney, Menjivar, Niello, Ochoa Bogh, Padilla, Pérez, Richardson, Rubio, Seyarto, Smallwood-Cuevas, Stern, Strickland, Umberg, Valladares, Wahab, Wiener
ABS, ABST OR NV: Alvarado-Gil, Becker, Hurtado, Jones, Reyes, Weber Pierson
ASM ENVIRONMENTAL SAFETY AND TOXIC MATERIALS: 7-0-0
YES: Connolly, Ellis, Bauer-Kahan, Castillo, Lee, McKinnor, Papan
ASSEMBLY FLOOR: 75-0-4
YES: Addis, Aguiar-Curry, Ahrens, Alanis, Alvarez, Arambula, Ávila Farías, Bains, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Caloza, Carrillo, Castillo, Chen, Connolly, Davies, DeMaio, Dixon, Elhawary, Ellis, Fong, Gabriel, Gallagher, Garcia, Gipson, Jeff Gonzalez, Mark González, Hadwick, Haney, Harabedian, Hart, Hoover, Irwin, Jackson, Kalra, Krell, Lackey, Lee, Lowenthal, Macedo, McKinnor, Muratsuchi, Nguyen, Ortega, Pacheco, Papan, Patel, Patterson, Petrie-Norris, Quirk-Silva, Ramos, Ransom, Celeste Rodriguez, Michelle Rodriguez, Rogers, Sanchez, Schiavo, Schultz, Sharp-Collins, Solache, Soria, Stefani, Ta, Tangipa, Valencia, Wallis, Ward, Wicks, Wilson, Zbur, Rivas
ABS, ABST OR NV: Bauer-Kahan, Flora, Pellerin, Blanca Rubio
UPDATED
VERSION: June 12, 2025
CONSULTANT: Naomi Ondrasek / E.S. & T.M. / (916) 319-3965 FN: 0001172
Date of Hearing: June 17, 2025
ASSEMBLY COMMITTEE ON ENVIRONMENTAL SAFETY AND TOXIC MATERIALS
Damon Connolly, Chair
SBPCA Bill Id:SB 39
Author:(Weber Pierson) – As Amended Ver:June 12, 2025
SENATE VOTE: 34-0
SUBJECT: Cosmetic safety: Vaginal suppositories
SUMMARY: Requires, commencing on January 1, 2027, a person or entity that manufactures or sells a vaginal boric acid suppository (BAS) product to include specified language on the product label; prohibits, beginning on January 1, 2035, a person or entity from manufacturing or selling a BAS product; provides that neither of these provisions apply if a BAS product becomes regulated as a drug under the United States Food and Drug Administration (FDA). Specifically, this bill:
- Makes several findings and declarations, including that:
- Intravaginal boric acid represents one of the few available options for addressing recurrent vaginal infections, and is included in multiple national guidelines, including guidelines issued by the American College of Obstetricians and Gynecologists;
- Existing state law bans, beginning January 1, 2027, the manufacture and sale of cosmetic products containing intentionally added boric acid; and,
- Because intravaginal boric acid represents one of the few available options for addressing recurrent vaginal infections, additional time for BAS is warranted, to allow these products time to become regulated as a drug under the FDA.
- Requires, commencing on January 1, 2027, a person or entity that manufactures, sells, delivers, holds, or offers for sale in commerce a vaginal suppository product containing intentionally added boric acid to include on the product label the following statement:
"WARNING: IT IS RECOMMENDED TO CONSULT WITH A DOCTOR BEFORE USE, particularly if you have sensitivity in your lower pelvis or abdomen, a sexually transmitted disease (STD), pelvic inflammatory disease (PID), vaginal bleeding, sores, ulcerations, nausea, fever, or chills. Do not use on broken or irritated skin. Stop use and contact a doctor if symptoms persist or worsen, or if you experience irritation, burning, bleeding, or cramping. NOT FOR ORAL CONSUMPTION. FOR VAGINAL USE ONLY. DO NOT USE IF PREGNANT, TRYING TO CONCEIVE, OR NURSING. IF YOU BECOME PREGNANT WHILE USING THIS PRODUCT, DISCONTINUE USE IMMEDIATELY. If swallowed, get medical help or contact Poison Control Center immediately. Some boric acid suppository products may break down a condom—ensure product has completely dissolved before having sex."
- Prohibits, commencing on January 1, 2035, a person or entity from manufacturing, selling, delivering, holding, or offering for sale in commerce a vaginal suppository product containing intentionally added boric acid.
- Provides that the above labeling requirement and prohibition do not apply to a vaginal suppository product containing intentionally added boric acid, if the product becomes regulated as a drug by the FDA.
- Defines "product label" to mean a display of written, printed, or graphic matter upon a cosmetic product or upon its immediate container.
- Provides that this bill is an urgency statute necessary for the immediate preservation of the public peace, health, or safety within the meaning of the California Constitution and shall go into immediate effect, in order for women in this state to have necessary medical and hygiene materials available to them in a timely manner.
EXISTING LAW:
- Prohibits, commencing January 1, 2025, a person or entity from manufacturing, selling, delivering, holding, or offering for sale in commerce any cosmetic product that contains any of 24 specified chemicals as intentionally added ingredients. (Health and Safety Code (HSC) § 108980(a))
- Prohibits, commencing January 1, 2027, a person or entity from manufacturing, selling, delivering, holding, or offering for sale in commerce any cosmetic product that contains any of 41 specified chemicals as intentionally added ingredients, including boric acid. (HSC § 108980(b))
- Provides that trace quantities of a chemical prohibited under HSC § 108980 shall not cause a cosmetic product to be in violation, if the trace quantity is technically unavoidable and stems from ingredient impurities, the manufacturing process, storage, or migration from packaging. (HSC § 108980(c))
- Defines, for the purposes of the federal Food, Drug, and Cosmetic Act (FD&C Act), "cosmetic" to mean:
- Articles intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to the human body or any part thereof for cleansing, beautifying, promoting attractiveness, or altering the appearance; and,
- Articles intended for use as a component of any such articles. (21 United States Code (USC) § 321(i))
- Defines, for the purposes of the FD&C Act, "drug" to mean:
- Articles recognized in any of several specified lists;
- Articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals;
- Articles (other than food) intended to affect the structure or any function of the body of man or other animals; and,
- Articles intended for use as a component of any such articles. (21 USC § 321(g)(1))
- Requires the label of a cosmetic product to bear a warning statement whenever necessary or appropriate to prevent a health hazard that may be associated with the product. (21 Code of Federal Regulations § 740.1(a))
- Requires a cosmetic to be deemed misbranded under specified circumstances, including if its labeling is false or misleading. (21 USC § 362)
- Prohibits the introduction or delivery for introduction into interstate commerce any drug or cosmetic that is adulterated or misbranded. (21 USC § 331(a))
FISCAL EFFECT: Unknown.
COMMENTS:
Need for the bill: According to the author:
"There is robust safety and efficacy data on the use of boric acid in vaginal products, so much so that they have been standard of care in women’s health for many years. For example, the Centers for Disease Control and Prevention (CDC) recommends the use of boric acid suppositories (BAS) in their current [sexually transmitted disease] guidelines (published 2015). Likewise, the American College of Obstetricians and Gynecologists (ACOG) recommends the use of BAS in vaginal health applications. Additionally, BAS are on the treatment protocols of many major academic and medical centers and/or are recommended for their patients (e.g., Kaiser Permanente, UCLA, Harvard, Columbia, Tufts, and American Association of Family Physicians).
Boric acid products are readily available at every major retailer in the US and are also available on Amazon. Healthcare providers guide their patients to purchase boric acid products at these retailers. Unless SB 39 is enacted, the ban on boric acid will prohibit women from accessing boric acid products and eliminate a woman’s right to choose how to manage her feminine health (especially in disadvantaged populations), eliminating a safe, effective, and accessible non-antibiotic treatment for conditions such as vaginal odor and yeast infections."
Boric acid, BAS, and vaginal infections: Boric acid is a naturally-occurring compound with antimicrobial properties. Due to its potential to cause reproductive harm, the European Union bans the use of boric acid in cosmetic products, and California's Department of Toxic Substances Control (DTSC) lists boric acid as a "candidate chemical" under its Safer Consumer Products program, which aims to advance the design, development, and use of products that are chemically safer for people and the environment. DTSC uses the Candidate Chemicals list to identify potential product-chemical combinations for future regulation.
Despite its potential for toxicity, boric acid is sometimes used in healthcare applications due to its antimicrobial properties. BAS are gelatin capsules containing boric acid, applied intravaginally to treat vaginal infections caused by yeast or bacteria, or to address vaginal odor (although some medical organizations, such as the Cleveland Clinic, state that vaginal odor is common and generally does not require treatment, except when the odor is strong and unfamiliar or unpleasant, which can signal a potential infection and is often accompanied by other symptoms).
BAS are easily available over-the-counter and, although they are often used to address vaginal infections, they are not currently regulated as drugs under the FDA. In 2021, researchers from the Johns Hopkins School of Medicine published the study, "Data on safety of intravaginal boric acid use in pregnant and non-pregnant women: A narrative review," in the journal Sexually Transmitted Diseases. In the study, the authors note that safety data specific to intravaginal boric acid use are sparse; however, the authors also note that intravaginal boric acid represents one of the only options available to treat recurrent vaginal infections caused by certain strains of drug resistant fungal and bacterial microbes. Intravaginal boric acid has been used for decades to treat vaginal infections. In addition, use of over-the-counter or clinician-recommended intravaginal boric acid is widespread, and may increase if microbial resistance to other treatment options rises.
In their review of studies examining the safety of intravaginal boric acid, the authors state the following:
- Available evidence suggests intravaginal use at dosages commonly described in the literature is likely safe for women, at least those with normal kidney function. However, the authors state that they "feel [intravaginal boric acid] should be prescribed by a provider" and that, given uncertainties, they cannot recommend unregulated use of over-the-counter products.
- Though limited, oral toxicity studies suggest that the amount of intravaginal boric acid required to induce significant toxicity in women would likely be more than the intravaginal doses commonly prescribed by clinicians to healthy adults.
- Guidelines from several medical professional and public health organizations, including the American College of Obstetricians and Gynecologists, advise that intravaginal boric acid use should be avoided in pregnancy.
- Although studies of the potential for intravaginal boric acid to cause birth defects in humans is "sparse and flawed," the authors state that high levels of oral consumption has been associated with birth defects in animals. As a result, the authors conclude that it is not possible to recommend, based on existing data, changes to guidelines advising against intravaginal boric acid use in pregnancy.
Federal regulation of cosmetics: Cosmetics are sold to consumers across California, including to young people in sensitive periods of development and women of childbearing age. These products are also often used on or in the body's most sensitive areas. As a result, thoughtful consideration of the ingredients used in cosmetics is important for ensuring that mothers, fetuses, nursing children, and adolescents are not exposed to chemicals that can cause cancer or reproductive toxicity.
At the federal level, the FD&C authorizes the FDA to oversee and regulate the production, sale, and distribution of food, drugs, medical devices, and cosmetics. Under the FD&C, a cosmetic is defined as an article "intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to the human body or any part thereof for cleansing, beautifying, promoting attractiveness, or altering the appearance," as well as any substance intended for use as a component in a cosmetic product. One of the FDA's primary tools for regulating cosmetics is the ability to prohibit the marketing of adulterated or misbranded cosmetics in interstate commerce. Adulteration refers to violations involving product composition, whether they result from ingredients, contaminants, processing, packaging, or shipping and handling. For example, a cosmetic is adulterated under the FD&C if "it bears or contains any poisonous or deleterious substance which may render it injurious to users under the conditions of use prescribed in the labeling thereof, or under conditions of use as are customary and usual." "Misbranding" refers to violations involving improperly labeled or deceptively packaged products. For example, a cosmetic may be deemed misbranded due to failure to provide material facts, including any directions for safe use and warning statements needed to ensure a product's safe use.
Federal regulation of cosmetics versus drugs: Products intended for a therapeutic use, such as treating or preventing disease, or to affect the structure or function of the body, are considered drugs under the FD&C. In some ways, the FDA's authority to regulate cosmetics is more limited than its authority to regulate drugs. Unlike drugs, cosmetic products and ingredients do not need FDA premarket approval, with the exception of color additives. In addition, for the most part, a manufacturer may use any ingredient in the formulation of a cosmetic, provided that the ingredient and the finished cosmetic are "safe under labeled or customary conditions of use"; the product is properly labeled; and use of the ingredient does not cause the cosmetic to be adulterated or misbranded under the FD&C. Neither the law nor regulations require specific tests to demonstrate the safety of individual cosmetic products or ingredients. In addition, the law also does not require cosmetic companies to register their cosmetic establishments, file their product formulations, or share their safety information with the FDA. The FD&C also does not authorize the FDA to compel companies to recall cosmetics.
State regulation of cosmetics: Before January 2021, California's primary law for governing the safety of cosmetics was the state's Sherman Food, Drug, and Cosmetic Law (Sherman Law). The Sherman Law (HSC § 109875, et seq.) is administered by the California Department of Public Health (CDPH) and serves as California's state level, implementing legislation for the federal FD&C. Under the Sherman Law, selling misbranded cosmetics can lead to civil and administrative penalties, embargoes, and even bans on products.
In addition, the California Safe Cosmetics Act of 2005 (Cosmetics Act; HSC § 111791, et seq.), housed under Sherman Law, requires manufacturers of any cosmetic product, sold into California and subject to regulation by the FDA, to provide CDPH with a complete and accurate list of cosmetic products that contain any ingredient that is a carcinogen or reproductive toxicant. The Cosmetics Act further requires CDPH to maintain a consumer-friendly, searchable online database that contains product information collected by CDPH pursuant to the Act.
In 2020, AB 2762 (Muratsuchi, Chapter 314) was signed into law, establishing a new body of statute that, independent of the state's Sherman Law, prohibits the manufacture or sale of cosmetic products containing any one of 24 chemicals as intentionally added ingredients. In 2023, AB 496 (Friedman, Chapter 441) added another 41 chemicals, including boric acid, to the list. For both bills, the aim was to prohibit chemicals in California that had already been banned from cosmetics in the European Union, due to their classification as substances with carcinogenic, mutagenic (i.e., capable of causing genetic mutations), or reproductive toxicity properties. This bill would provide manufacturers of BAS, which contain intentionally added boric acid, with an additional eight years before the prohibition takes effect, to allow them time to undergo the FDA's drug development and review process (described further below) and become regulated as drugs under the FD&C.
FDA action on BAS: When the FDA identifies what it believes are significant violations of federal requirements, it notifies the appropriate party, often through a "warning letter." Warning letters identify the concern (such as poor manufacturing practices, problems with claims for what a product can do, or incorrect directions for use). In August 2018, the FDA issued a warning letter to Vireo Resources regarding its product, pH-D Feminine Health Support Boric Acid Vaginal Suppositories. In the letter, in a section entitled "Unapproved New Drug and Misbranded Drug," the FDA states:
"Statements on your website…establish that pH-D Feminine Health Support Boric Acid Vaginal Suppositories is a drug as defined [under the FD&C], because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or to affect the structure or function of the body…New drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from the FDA…No approved application pursuant to section 505 of the Act [21 U.S.C. § 355] is in effect for this product…
Your pH-D Feminine Health Support Boric Acid Vaginal Suppositories is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, adequate directions for use cannot be written so that a layperson can use your product safely for its intended purposes. Accordingly, pH-D Feminine Health Support Boric Acid Vaginal Suppositories fails to bear adequate directions for its intended uses and, therefore, the product is misbranded under [the FD&C]."
At the time of the writing of this analysis, some manufacturers are in the process of pursuing FDA drug approval for their BAS products.
Multi-year drug development and review process under the FDA: Current state law bans the manufacture and sale of cosmetic products containing intentionally added boric acid, beginning on January 1, 2027. This bill provides manufacturers of BAS products with an additional eight years before they are banned under state law, to provide them with time to undergo the FDA's drug development and review process and pursue status and regulation as an FDA-approved drug. As stated in the bill's findings and declarations, this extension is based on research showing that intravaginal boric acid represents one of the few available options for addressing recurrent vaginal infections, as well as recommendations—issued by professional medical associations such as the American College of Obstetricians and Gynecologists—for the use of BAS products. To provide a layer of consumer protection while manufacturers pursue regulation of their BAS products as drugs under the FDA, this bill further requires that manufacturers label their products with information pertaining to the safe use of BAS, including that these products should not be used during pregnancy, or while nursing or trying to conceive.
The FDA's drug development and review process can take a number of years to complete and includes numerous steps. According to the FDA, the clinical trials stage often takes the longest time, usually multiple years. If a drug receives FDA approval, it then becomes subject to FDA regulatory oversight, in which the FDA monitors real-time data from patients, drug manufacturers, and healthcare professionals, including reports of adverse reactions. Based on these data, the FDA can take various actions, including updating drug labeling requirements to ensure safe use and issuing drug recalls.
Potential drugs must typically undergo the following steps before federal approval:
- Preclinical (animal) testing: Before testing a potential drug in people, researchers use animal or in vitro (e.g., cell-based) models to determine dosing levels and whether a potential drug may cause serious harm, or toxicity, in humans.
- Submission of an Investigational New Drug application (IND): The IND outlines what the sponsor (company, research institution, or other organization) of a new drug proposes for human testing in clinical trials. Sponsors must show the FDA results of preclinical testing in laboratory animals; the FDA then decides whether it is reasonably safe for the company to move forward with testing the drug in humans via clinical trials.
- Clinical trials: Clinical studies are conducted in humans and can begin only after an IND is reviewed by the FDA and a local institutional review board (a panel of scientists and non-scientists in hospitals and research institutions that oversee clinical research). This stage consists of three phases:
- Phase 1: These studies usually involve 20-80 healthy volunteers and are aimed at identifying common side effects, as well as how the human body processes a drug;
- Phase 2: These studies begin if Phase 1 does not reveal unacceptable toxicity. While the emphasis in Phase 1 is on safety, the emphasis in Phase 2 is on effectiveness. This phase aims to obtain preliminary data on whether the drug works in people who have a certain disease or condition. Patients receiving the drug are compared with similar patients receiving a different treatment, usually a placebo. Typically, the number of subjects in Phase 2 studies ranges from a few dozen to about 300. At the end of Phase 2, the FDA and sponsors try to come to an agreement on how large-scale studies in Phase 3 should be done.
- Phase 3: Phase 3 studies begin if Phase 2 produces evidence of effectiveness. These studies gather more information about safety and effectiveness, studying different populations and different dosages and using the drug in combination with other drugs. The number of subjects usually ranges from several hundred to 3,000 people.
- Submission of an NDA and FDA review: This is the formal step a drug sponsor takes to ask that the FDA consider approving a new drug for marketing in the United States. A drug developer must include everything about a drug—from preclinical data to Phase 3 clinical trial data—in an NDA. Developers must also include reports on all studies, data, and analyses; proposed labeling; and directions for use, among other things.
- Post-market drug safety monitoring: After the FDA has approved a product for marketing, post-market monitoring and studies are required of or agreed to by a sponsor. The FDA uses post-market monitoring and studies to gather additional information about a product's safety, efficacy, or optimal use.
This bill: Because BAS represents one of the few options available to treat recurrent vaginal infections caused by drug resistant microbes, SB 39 allots additional time for manufacturers of BAS products to undergo the FDA's drug development and review process, before these products are banned under existing law that prohibits the manufacture or sale of cosmetics containing intentionally added boric acid. Further, the bill provides that BAS products that become regulated under the FDA as a drug would not be subject to the ban on cosmetics containing intentionally added boric acid. Finally, this bill provides a layer of consumer protection while manufacturers work towards FDA drug approval, by requiring these products to bear a label containing information about the safe use of BAS. Overall, SB 39 takes a targeted approach to preserving women's ability to access BAS products, without weakening state laws aimed at protecting consumers from cosmetics containing chemicals with known carcinogenic, mutagenic, and reproductive toxicity traits.
Arguments in support: According to the California Pan-Ethnic Health Network:
"Boric acid suppositories are a long-standing, evidence-based, effective and affordable treatment option for managing yeast infections and bacterial vaginosis—conditions that disproportionately affect low-income women of color who face systemic barriers to health care. Current regulations on cosmetic products as created by AB 2762 (Muratsuchi, Chapter 314, Statutes of 2020) and amended by AB 496 (Friedman, Chapter 441, Statutes of 2023) exclude boric acid, forcing many individuals to choose between unregulated markets or untreated infections which can lead to severe reproductive complications. SB 39 would add a necessary and thoughtful update to California’s regulations for cosmetic products and ensure access to boric acid in gynecological care."
Arguments in opposition: None on file.
Related legislation:
- AB 60 (Papan). Prohibits, commencing January 1, 2027, a person or entity from manufacturing, selling, delivering, holding, or offering for sale in commerce any cosmetic product that contains any of five specified ingredients. This bill is pending in the Senate Environmental Quality Committee.
- AB 496 (Friedman, Chapter 441, Statutes of 2023). Prohibits, beginning January 1, 2027, the manufacture, sale, delivery, holding, or offering for sale in commerce of any cosmetic product containing 41 specified intentionally added ingredients.
- AB 2771 (Friedman, Chapter 804, Statutes of 2022). Prohibits any person or entity from manufacturing, selling, delivering, holding, or offering for sale in commerce any cosmetic product that contains any per- or polyfluoroalkyl substance.
- AB 2762 (Muratsuchi, Chapter 314, Statutes of 2020). Prohibits, beginning January 1, 2025, the manufacture, sale, delivery, holding, or offering for sale in commerce of any cosmetic product containing 24 specified intentionally added ingredients.
REGISTERED SUPPORT / OPPOSITION:
Support
California Pan - Ethnic Health Network
Opposition
None on file
Analysis Prepared by: Naomi Ondrasek / E.S. & T.M. / (916) 319-3965
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | SB 39 |
CONSENT
Bill No: SB 39
Author: Weber Pierson (D)
Amended: 2/11/25
Vote: 27 - Urgency
SENATE ENVIRONMENTAL QUALITY COMMITTEE: 8-0, 3/19/25
AYES: Blakespear, Valladares, Dahle, Gonzalez, Hurtado, Menjivar, Padilla, Pérez
SUBJECT: Cosmetic safety: Vaginal or vulvar products
SOURCE: Author
DIGEST:
This bill exempts vaginal or vulvar products containing boric acid from the ban on cosmetic products as created by AB 2762 (Muratsuchi, Chapter 314, Statutes of 2020) and amended by AB 496 (Friedman, Chapter 441, Statutes of 2023) if specified conditions are met.
ANALYSIS:
Existing federal law requires, pursuant to the federal Food, Drug & Cosmetic Act (FD&C Act), cosmetics produced or distributed for retail sale to consumers for their personal care to bear an ingredient declaration. (21 Code of Federal Regulations 701.3)
Existing state law:
- Defines, pursuant to the Sherman Act, "cosmetic" as any article, or its components, intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to, the human body, or any part of the human body, for cleansing, beautifying, promoting attractiveness, or altering the appearance. Further, the law makes it unlawful for any person to manufacture, sell, deliver, hold, or offer for sale any cosmetic that is adulterated or for any person to adulterate any cosmetic. (Health & Safety Code (HSC) § 109900)
- Requires, pursuant to the Safe Consumer Cosmetic Act (Cosmetics Act), a manufacturer of a cosmetic that is subject to regulation by the federal Food and Drug Administration (FDA) to submit to the California Department of Public Health (CDPH) a list of its cosmetic products sold in California that contain any ingredient that is a chemical identified as causing cancer or reproductive toxicity. (HSC § 111792)
- Requires the Department of Toxic Substances Control (DTSC), under the state's Green Chemistry regulations, to establish a process to identify and prioritize chemicals or chemical ingredients in consumer products that may be considered a chemical of concern. (HSC § 25252)
- Requires DTSC to develop and maintain a list of Candidate Chemicals that exhibit a hazard trait and/or an environmental or toxicological endpoint and is either a) found on one or more of the statutorily specified authoritative lists or b) is listed by DTSC using specified criteria. (California Code of Regulations § 69502.2 (b))
- Prohibits a person or entity from manufacturing, selling, delivering, holding, or offering for sale in commerce any cosmetic product that contains 24 specified intentionally added chemical ingredients commencing January 1, 2025. Further, prohibits a person or entity from manufacturing, selling, delivering, holding, or offering for sale in commerce any cosmetic product that contains 41 specified intentionally added chemical ingredients commencing January 1, 2027. (HSC § 108980)
This bill:
- Exempts vaginal or vulvar products from the prohibitions of manufacturing, selling, delivering, holding, or offering for sale in commerce any cosmetic product containing the intentionally added ingredients specified in subparagraph (B) of paragraph (19) of subdivision (b) of Section 108980 of the HSC if any of the specified conditions are met including:
- The product undergoes clinical trials for regulation by the United States FDA.
- The product has a pending new drug application under the Federal Food, Drug, and Cosmetic Act.
- The product becomes regulated as a drug by the FDA.
- The product has passed definitive third-party placebo-controlled double-blind safety trials.
- Makes related findings and declarations.
Background
- Regulatory requirements for California’s cosmetics. Prior to 2020, California had two laws governing the safety of cosmetics: The Sherman Act and the Cosmetics Act. These laws focused on the identification and notification of hazardous chemicals in cosmetics and outlawing the tampering of products. The Sherman Act prohibits the manufacture, sale, delivery, hold, or offer for sale of any cosmetic that is adulterated and makes it unlawful for any person to adulterate any cosmetic. The Cosmetic Act, established by SB 484 (Migden, Chapter 729, Statutes of 2005), requires the manufacturer, packer, and/or distributor of cosmetic products to provide the CDPH a list of all cosmetic products that contain any ingredient known or suspected to cause cancer, birth defects, or other reproductive harm. CDPH does not have any enforcement authority over the manufacturers that are covered, so compliance may be lacking.
- Chemical bans for cosmetics. Over the past several years, California has shifted its approach to the regulation of cosmetics. Section 108980 of the Health and Safety Code, as established by AB 496 (Friedman, Chapter 441, Statutes of 2023) and AB 2762 (Muratsuchi, Chapter 314, Statutes of 2020), prohibits the manufacture, sale, delivery, holding, or offering for sale in commerce any cosmetic product that contains any of 65 intentionally added ingredients. This approach is meant to reflect the hazard-based, regulatory framework of the European Union (EU) and leads to the banning of hazardous chemicals in cosmetics. On September 15, 2022, the European Commission (EC) published Regulation EU 2022/1531 to amend Cosmetics Regulation EC No. 1223/2009 for the use of certain ingredients classified as carcinogenic, mutagenic, or toxic for reproduction (CMR substances) in cosmetic products.
These regulations require EU member states to prohibit the marketing of cosmetic products containing these ingredients. The scope of products covered under the EU's definition of cosmetics is broader than the scope of products covered under California's definition of cosmetics.
- The use of boric acid in suppositories. Boric acid is a naturally occurring chemical that is associated with antifungal activity and can quickly kill 50-90% of certain fungi.[1] Boric acid suppositories (BAS) are gelatin capsules of boric acid applied intravaginally and said to address vaginal odor and infections, such as yeast infections and bacterial vaginosis. BAS are marketed as a natural remedy and an alternative to pharmaceuticals. They are sometimes encouraged for use when other viable treatment options have been exhausted and for stubborn and recurrent infections.[2] Boric acid is recommended for use against atypical species of fungi and more severe infections.[3] Only 5-10% of yeast infections are caused by atypical species.3 The Centers for Disease Control (CDC) and Prevention and the American College of Obstetricians and Gynecologists (ACOG) recommend the use of boric acid in a gelatin capsule only after recurrence of a yeast infection caused by atypical fungi species and after longer periods of treatment via other methods.3,[4] BAS are considered to be effective as experimental results have demonstrated that these products can lead to relief from symptoms of vaginal infections within 48 hours.[5]
Though useful in suppositories, boric acid has been considered reproductively toxic over the last 50 years.[6] Boric acid was added to the List of Substances Prohibited in Cosmetic Products (Annex II) in the EU in 2022. There, it is classified as a reproductive toxicant and BAS is currently not available for purchase in the EU. Boric acid is also identified as a Candidate Chemical for the California DTSC. The Expert Panel for Cosmetic Ingredient Safety concluded that boric acid in concentrations less than or equal to 5% is safe.5 The capsules of BAS typically contain 0.6 grams of boric acid and are considered safe for use as 15 grams of boric acid can have toxic effects.[7],[8] Because BAS are administered intravaginally, the risk of introducing the toxic chemical to other parts of the body is lower, however, there is a risk of introducing the toxic chemical into the bloodstream if there is damage to the vaginal wall.1,5 There are side effects of BAS including increased irritation, burning, and vaginal discharge.
Boric acid use is not recommended for pregnant women, as there is limited data on its harmful effects. Experts recommend that affected individuals consult their healthcare provider before using BAS to treat infections. Researchers claim that BAS should not be considered for the first-line treatment of uncomplicated vaginal infections because of insufficient data, controversy surrounding safety, and the availability of safer and effective treatments.1 Because of its potential ability to impair fertility, researchers also suggest boric acid be considered a last option in exceptional cases for non-pregnant women.[9],[10] The alternatives to BAS include prescribed antifungal and antibacterial medication, probiotics, and diets incorporating fermented food.
- A controversial capsule. BAS are currently not approved by the U.S. FDA and have not been rigorously tested to ensure that they are safe and effective for use. Their status with the FDA classifies BAS as homeopathic products, which are not required to be reviewed by the FDA. Homeopathic products tend to pose higher risks to public health because they may contain unsafe ingredients, undergo improper and unregulated manufacturing, have contamination, and lack labels that inform consumers of risks and side effects. BAS also tend to be marketed to treat and prevent infections, which could qualify these products as drugs. Under the Federal Food, Drug, and Cosmetic Act, products marketed in this manner and without FDA approval would violate federal law. In 2018, the FDA issued a warning to a manufacturer of a BAS product sold by the sponsor of this bill (pH-D Feminine Health) claiming that the online marketing of their product characterized their product as a drug. This was based on the manner in which the product is administered and the ailments it addresses. The manufacturer argued that the product has long been considered a cosmetic and should be regulated as such. The sponsor also alleges that they were advised incorrectly on acceptable marketing. As a result, the FDA required the product to undergo clinical trials and the manufacturer began to market the product as a cosmetic that solely addresses vaginal odor.
In 2024, a class action lawsuit was filed against manufacturers for illegally selling BAS marketed to treat and prevent infections without FDA approval. Additionally in 2024, Women’s Voices for the Earth, on behalf of several health and advocacy organizations, issued a letter of concern to a healthcare manufacturer to remove boric acid from their intimate care products over concerns of reproductive safety and to stop the spread of misinformation. This class action lawsuit is still pending.
Comments
- Purpose of Bill. According to the author, “SB 39 will allow boric acid to continue to be used in vaginal and vulvar products sold in the State of California, and ultimately nationwide, as national retailers do not sell state-specific products. These products are marketed as cosmetics and are used by healthcare providers to treat two of the most common issues affecting women: vaginal yeast infections and vaginal odor. There is robust safety and efficacy data on the use of boric acid products in vaginal and vulvar products. For example, the CDC and Prevention recommends the use of BAS in their current STD guidelines (published 2015). Likewise, The ACOG recommends the use of BAS in vaginal health applications. Boric acid products are readily available at every major retailer in the US. Healthcare providers guide their patients to purchase boric acid products at these retailers. Data shows that in areas where healthcare deserts exist, the sales of boric acid products are significantly higher, as well as healthcare providers instructing their patients to purchase these affordable products. Unless SB 39 is enacted, the ban on boric acid will prohibit women from accessing boric acid products and eliminate a woman’s right to choose how to manage her feminine health (especially in disadvantaged populations), eliminating a safe, effective, and accessible non-antibiotic treatment for conditions such as vaginal odor and yeast infections.”
- Accessibility to over-the-counter medications. Boric acid suppositories are sold over the counter and do not require a prescription from a healthcare provider. This leaves an option for affected individuals to receive treatment and relief without a visit to the doctor. This is an important consideration given that 8% of women in California do not have access to health insurance and would not be prescribed alternative treatment options.[11] If these products are unavailable to current consumers, there is also the potential for affected individuals to seek boric acid intended for other applications to make homemade suppositories, which could put these individuals at a higher risk. Some research has claimed that BAS could be a safe and economic option for women with recurrent and chronic symptoms of vaginitis when conventional treatment fails with atypical, resistant strains of fungi.2,[12] However, given that there are concerns surrounding the hazardous nature of boric acid, insufficient data on safety, and that it is listed as a reproductive toxicant on the EU's List of Substances Prohibited in Cosmetic Products and the Candidate Chemical list for DTSC, more transparency could protect consumers and allow them to make an informed choice regarding the substances they introduce into their bodies.
- Drugs or cosmetics, boric acid still burns. Arguments have been made that the products should forgo the rigorous testing and approval process of the FDA because they can be classified as cosmetics. BAS capsules still contain a reproductively hazardous toxicant, so regardless of whether BAS is classified as a drug or a cosmetic, the capsules need to be regulated. It is laudable that the author proposes any exceptions that involve vaginal products containing boric acid to be regulated as a drug by the FDA or undergo safety trials, however, these products will be left on the market unregulated and without a warning label while undergoing clinical trials or pending a new drug application.
- When helping hurts: hazard vs. risk. The controversy surrounding BAS highlights the shortcomings in our approach to not only define potentially hazardous products in statute but also in considering hazards and risks. The prohibited chemicals in the EU Directive are evaluated based on hazard, or the potential to cause harm, whereas the U.S. evaluates chemicals on risk, or the likelihood to cause harm. This results in outright bans in the EU as opposed to safety assessments and concentration limits in the U.S. AB 2762 (Muratsuchi, Chapter 314, Statutes of 2020) and AB 496 (Friedman, Chapter 441, Statutes of 2023) were efforts to align California's regulations with hazard-based assessments of the EU rather than risk-based assessments. Though this tends to be unfavorable with industries in California, prohibiting toxic chemicals has led to the development of alternative ingredients or the removal of toxic ingredients in the EU, and furthermore the increase in access to safer products.
The question before the legislature is to decide whether the risks associated with these products are worth the cost of potentially harming affected individuals. Due to the controversy surrounding boric acid, hazards associated with boric acid, and guidance suggested by experts, the uncodified declarations and findings are partial, uncomprehensive, and do not consider the nuance in the use of BAS.
Related/Prior Legislation
AB 496 (Friedman, Chapter 441, Statutes of 2023) prohibits, beginning January 1, 2027, the manufacture, sale, delivery, holding, or offering for sale in commerce of any cosmetic product containing 41 specified intentionally added ingredients.
AB 2771 (Friedman, Chapter 804, Statutes of 2022) prohibits any person or entity from manufacturing, selling, delivering, holding, or offering for sale in commerce any cosmetic product that contains any per- or polyfluoroalkyl substance (PFAS).
AB 2762 (Muratsuchi, Chapter 314, Statutes of 2020) prohibits, beginning January 1, 2025, the manufacture, sale, delivery, holding, or offering for sale in commerce of any cosmetic product containing 24 specified intentionally added ingredients.
FISCAL EFFECT: Appropriation: No Fiscal Com.: No Local: No
SUPPORT: (Verified 3/20/25)
American Congress of Obstetricians and Gynecologists - District IX
Nutrablast
Ph-d Feminine Health, LLC
The Flex Company
OPPOSITION: (Verified 3/20/25)
None received
Prepared by: Taylor McKie / E.Q. / (916) 651-4108,
3/21/25 16:13:41
**** END ****
Prutting, S. M., & Cerveny, J. D. (1998). Boric acid vaginal suppositories: a brief review. Infectious diseases in obstetrics and gynecology, 6(4), 191. ↑
Iavazzo, C., Gkegkes, I. D., Zarkada, I. M., & Falagas, M. E. (2011). Boric acid for recurrent vulvovaginal candidiasis: the clinical evidence. Journal of women's health, 20(8), 1245-1255. ↑
Paavonen, J. A., & Brunham, R. C. (2020). Vaginitis in nonpregnant patients: ACOG practice bulletin number 215. Obstetrics & Gynecology, 135(5), 1229-1230. ↑
Centers for Disease Control and Prevention. (2021). Vulvovaginal Candidiasis. www.cdc.gov/std/treatment-guidelines/candidiasis.htm#print ↑
Writer, C. I. R. (2024). Safety Assessment of Boric Acid and Sodium Borate as Used in Cosmetics. ↑
Chapin, R. E., & Ku, W. W. (1994). The reproductive toxicity of boric acid. Environmental health perspectives, 102(suppl 7), 87-91. ↑
Farfán-García, E. D., Castillo-Mendieta, N. T., Ciprés-Flores, F. J., Padilla-Martínez, I. I., Trujillo-Ferrara, J. G., & Soriano-Ursúa, M. A. (2016). Current data regarding the structure-toxicity relationship of boron-containing compounds. Toxicology letters, 258, 115-125. ↑
Sevim, Ç., & Kara, M. (2022). Boron and boron-containing compounds toxicity. In The Toxicity of Environmental Pollutants. IntechOpen. ↑
Donders, G., Sziller, I. O., Paavonen, J., Hay, P., de Seta, F., Bohbot, J. M., ... & Mendling, W. (2022). Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion. Frontiers in Cellular and Infection Microbiology, 12, 934353. ↑
Farr, A., Effendy, I., Frey Tirri, B., Hof, H., Mayser, P., Petricevic, L., ... & Mendling, W. (2021). Guideline: vulvovaginal candidosis (AWMF 015/072, level S2k). Mycoses, 64(6), 583-602. ↑
KFF (2023). California Women’s Health Insurance Coverage Data ↑
Mittelstaedt, R., Kretz, A., Levine, M., Handa, V. L., Ghanem, K. G., Sobel, J. D., ... & Tuddenham, S. (2021). Data on safety of intravaginal boric acid use in pregnant and nonpregnant women: a narrative review. Sexually transmitted diseases, 48(12), e241-e247. ↑
SENATE COMMITTEE ON ENVIRONMENTAL QUALITY
Senator Blakespear, Chair
2025 - 2026 Regular
Bill No: SB 39
Author: | Weber Pierson | ||
Version: | 02/11/2025 | Hearing Date: | 3/19/2025 |
Urgency: | Yes | Fiscal: | No |
Consultant: | Taylor McKie | ||
SUBJECT: Cosmetic safety: Vaginal or vulvar products
DIGEST: This bill exempts vaginal or vulvar products containing boric acid from the ban on cosmetic products as created by AB 2762 (Muratsuchi, Chapter 314, Statutes of 2020) and amended by AB 496 (Friedman, Chapter 441, Statutes of 2023) if specified conditions are met.
ANALYSIS:
Existing federal law:
- Requires, pursuant to the federal Food, Drug & Cosmetic Act (FD&C Act), cosmetics produced or distributed for retail sale to consumers for their personal care to bear an ingredient declaration. (21 Code of Federal Regulations 701.3)
Existing state law:
- Defines, pursuant to the Sherman Act, "cosmetic" as any article, or its components, intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to, the human body, or any part of the human body, for cleansing, beautifying, promoting attractiveness, or altering the appearance. Further, the law makes it unlawful for any person to manufacture, sell, deliver, hold, or offer for sale any cosmetic that is adulterated or for any person to adulterate any cosmetic. (Health & Safety Code (HSC) § 109900)
- Requires, pursuant to the Safe Consumer Cosmetic Act (Cosmetics Act), a manufacturer of a cosmetic that is subject to regulation by the federal Food and Drug Administration (FDA) to submit to the California Department of Public Health (CDPH) a list of its cosmetic products sold in California that contain any ingredient that is a chemical identified as causing cancer or reproductive toxicity. (HSC § 111792)
- Requires the Department of Toxic Substances Control (DTSC), under the state's Green Chemistry regulations, to establish a process to identify and prioritize chemicals or chemical ingredients in consumer products that may be considered a chemical of concern. (HSC § 25252)
- Requires DTSC to develop and maintain a list of Candidate Chemicals that exhibit a hazard trait and/or an environmental or toxicological endpoint and is either 1) found on one or more of the statutorily specified authoritative lists or 2) is listed by DTSC using specified criteria. (California Code of Regulations § 69502.2 (b))
- Prohibits a person or entity from manufacturing, selling, delivering, holding, or offering for sale in commerce any cosmetic product that contains 24 specified intentionally added chemical ingredients commencing January 1, 2025. Further, prohibits a person or entity from manufacturing, selling, delivering, holding, or offering for sale in commerce any cosmetic product that contains 41 specified intentionally added chemical ingredients commencing January 1, 2027. (HSC § 108980)
This bill:
- Exempts vaginal or vulvar products from the prohibitions of manufacturing, selling, delivering, holding, or offering for sale in commerce any cosmetic product containing the intentionally added ingredients specified in subparagraph (B) of paragraph (19) of subdivision (b) of Section 108980 of the Health and Safety Code if any of the specified conditions are met including:
- The product undergoes clinical trials for regulation by the United States Food and Drug Administration (FDA).
- The product has a pending new drug application under the Federal Food, Drug, and Cosmetic Act.
- The product becomes regulated as a drug by the FDA.
- The product has passed definitive third-party placebo-controlled double-blind safety trials.
- Makes related findings and declarations.
Background
- Regulatory requirements for California’s cosmetics. Prior to 2020, California had two laws governing the safety of cosmetics: The Sherman Act and the Cosmetics Act. These laws focused on the identification and notification of hazardous chemicals in cosmetics and outlawing the tampering of products. The Sherman Act defines cosmetics as any article, or its components, intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to, the human body, or any part of the human body, for cleansing, beautifying, promoting attractiveness, or altering the appearance. The Sherman Act prohibits the manufacture, sale, delivery hold, or offer for sale of any cosmetic that is adulterated and makes it unlawful for any person to adulterate any cosmetic. The law also considers any cosmetic to be adulterated, “if it bears or contains any poisonous or deleterious substance that may render it injurious to users.”
The Cosmetic Act, established by SB 484 (Migden, Chapter 729, Statutes of 2005), requires the manufacturer, packer, and/or distributor of cosmetic products to provide the California Department of Public Health (CDPH) a list of all cosmetic products that contain any ingredient known or suspected to cause cancer, birth defects, or other reproductive harm. CDPH maintains an active, searchable database with all of the data collected from manufacturers and makes that data available to the public. CDPH does not have any enforcement authority or penalty authority over the manufacturers that are covered, so not all manufacturers are currently complying and submitting their products' information. State law does not currently contain a mechanism that would allow the state to compel these manufacturers to comply.
- Chemical bans for cosmetics. Over the past several years, California has shifted its approach to the regulation of cosmetics. Section 108980 of the Health and Safety Code, as established by AB 496 (Friedman, Chapter 441, Statutes of 2023) and AB 2762 (Muratsuchi, Chapter 314, Statutes of 2020), prohibits the manufacture, sale, delivery, holding, or offering for sale in commerce any cosmetic product that contains any of 65 intentionally added ingredients.
This approach is meant to reflect the hazard-based, regulatory framework of the European Union (EU) and leads to the banning of hazardous chemicals in cosmetics. On September 15, 2022, the European Commission published Regulation (EU) 2022/1531 to amend Cosmetics Regulation (EC) No. 1223/2009 for the use of certain ingredients classified as carcinogenic, mutagenic, or toxic for reproduction (CMR substances) in cosmetic products.
These regulations require EU member states to prohibit the marketing of cosmetic products containing these ingredients. The regulation defines “cosmetic product” as “any substance or mixture intended to be placed in contact with the external parts of the human body (epidermis, hair system, nails, lips and external genital organs) or with the teeth and the mucous membranes of the oral cavity with a view exclusively or mainly to cleaning them, perfuming them, changing their appearance, protecting them, keeping them in good condition or correcting body odors.” The scope of products covered under the EU's definition of cosmetics is broader than the scope of products covered under California's definition of cosmetics.
Vaginal or vulvar products containing boric acid are not regulated under the Sherman Act or the Cosmetic Act, but the bans established by AB 496 (Friedman, Chapter 441, Statutes of 2023) and AB 2762 (Muratsuchi, Chapter 314, Statutes of 2020) bring these products under regulation.
- The use of boric acid in suppositories. Boric acid is a naturally occurring chemical that is associated with antifungal activity and can quickly kill 50-90% of certain fungi.[1] Boric acid suppositories (BAS) are gelatin capsules of boric acid applied intravaginally and said to address vaginal odor and infections, such as yeast infections and bacterial vaginosis. BAS are marketed as a natural remedy and an alternative to pharmaceuticals. They are sometimes encouraged for use when other viable treatment options have been exhausted and for stubborn and recurrent infections.[2] Boric acid is recommended for use against atypical species of fungi and more severe infections.[3] Only 5-10% of yeast infections are caused by atypical species.3 The Centers for Disease Control and Prevention (CDC) and the American College of Obstetricians and Gynecologists (ACOG) recommend the use of boric acid in a gelatin capsule only after recurrence of a yeast infection caused by atypical fungi species and after longer periods of treatment via other methods.3,[4] BAS are considered to be effective as experimental results have demonstrated that these products can lead to relief from symptoms of vaginal infections within 48 hours.[5]
Though useful in suppositories, boric acid has been considered reproductively toxic over the last 50 years.[6] Boric acid was added to the List of Substances Prohibited in Cosmetic Products (Annex II) in the EU in 2022. There, it is classified as a reproductive toxicant and BAS is currently not available for purchase in the EU. Boric acid is also identified as a Candidate Chemical for the California Department of Toxic Substances Control (DTSC). The Expert Panel for Cosmetic Ingredient Safety concluded that boric acid in concentrations less than or equal to 5% is safe.5 The capsules of BAS typically contain 0.6 grams of boric acid and are considered safe for use as 15 grams of boric acid can have toxic effects.[7],[8] Because BAS are administered intravaginally, the risk of introducing the toxic chemical to other parts of the body is lower, however, there is a risk of introducing the toxic chemical into the bloodstream if there is damage to the vaginal wall.1,5 There are side effects of BAS including increased irritation, burning, and vaginal discharge. Because of their similar appearance to oral medicine capsules and inconspicuous labeling, there have been cases of accidental ingestion, which can lead to serious harm or death if multiple capsules are swallowed.
Boric acid use is not recommended for pregnant women, as there is limited data on its harmful effects. Experts recommend that affected individuals consult their healthcare provider before using BAS to treat infections. Researchers claim that BAS should not be considered for the first-line treatment of uncomplicated vaginal infections because of insufficient data, controversy surrounding safety, and the availability of safer and effective treatments.1 Because of its potential ability to impair fertility, researchers also suggest boric acid be considered a last option in exceptional cases for non-pregnant women.[9],[10] The alternatives to BAS include prescribed antifungal and antibacterial medication, probiotics, and diets incorporating fermented food.
- A controversial capsule. BAS are currently not approved by the U.S. Food and Drug Administration (FDA) and have not been rigorously tested to ensure that they are safe and effective for use. Their status with the FDA classifies BAS as homeopathic products, which are not required to be reviewed by the FDA. Homeopathic products tend to pose higher risks to public health because they may contain unsafe ingredients, undergo improper and unregulated manufacturing, have contamination, and lack labels that inform consumers of risks and side effects. Impurities, such as sulfate and other metals, could be introduced in the processing and manufacturing of boric acid.[11] Because BAS are unregulated, they may not include information about risks and side effects on their packaging and labeling.
BAS also tend to be marketed to treat and prevent infections, which could qualify these products as drugs. Under the Federal Food, Drug, and Cosmetic Act, products marketed in this manner and without FDA approval would violate federal law. In 2018, the FDA issued a warning to a manufacturer of a BAS product sold by the sponsor of this bill (pH-D Feminine Health) claiming that the online marketing of their product characterized their product as a drug. This was based on the manner in which the product is administered and the ailments it addresses. The manufacturer argued that the product has long been considered a cosmetic and should be regulated as such. The sponsor also alleges that they were advised incorrectly on acceptable marketing. As a result, the FDA required the product to undergo clinical trials and the manufacturer began to market the product as a cosmetic that solely addresses vaginal odor. Additionally, the language on product use and non-use for pregnant women was strengthened on their labeling.
In 2024, a class action lawsuit was filed against manufacturers for illegally selling BAS marketed to treat and prevent infections without FDA approval. Additionally in 2024, Women’s Voices for the Earth, on behalf of several health and advocacy organizations, issued a letter of concern to a healthcare manufacturer to remove boric acid from their intimate care products (mainly vaginal washes and odor products) over concerns of reproductive safety and to stop the spread of misinformation. This class action lawsuit is still pending.
Comments
- Purpose of Bill. According to the author, “SB 39 will allow boric acid to continue to be used in vaginal and vulvar products sold in the State of California, and ultimately nationwide, as national retailers do not sell state-specific products. Boric acid is a naturally occurring, mild (weak) acid that has been safely used in vaginal and vulvar products for decades. These products are marketed as cosmetics and are used by healthcare providers to treat two of the most common issues affecting women: vaginal yeast infections and vaginal odor. There is robust safety and efficacy data on the use of boric acid products in vaginal and vulvar products so much so that they have been the standard of care in women’s health for many years. For example, the Centers for Disease Control and Prevention (CDC) recommends the use of boric acid suppositories (BAS) in their current STD guidelines (published 2015). Likewise, The American College of Obstetrics and Gynecology (ACOG) recommends the use of boric acid suppositories (BAS) in vaginal health applications. Additionally, BAS are on the treatment protocols of many major academic and medical centers and/or are recommended for their patients (E.g., Kaiser Permanente, UCLA, Harvard, Columbia, Tufts, and American Association of Family Physicians). Boric acid products are readily available at every major retailer in the US and are also available on Amazon. Healthcare providers guide their patients to purchase boric acid products at these retailers. Data shows that in areas where healthcare deserts exist, the sales of boric acid products are significantly higher due to lack of access to healthcare, as well as healthcare providers instructing their patients to purchase these affordable products. Unless SB 39 is enacted, the ban on boric acid will prohibit women from accessing boric acid products and eliminate a woman’s right to choose how to manage her feminine health (especially in disadvantaged populations), eliminating a safe, effective, and accessible non-antibiotic treatment for conditions such as vaginal odor and yeast infections.”
- Accessibility to over-the-counter medications. Boric acid suppositories and other vaginal products containing boric acid are sold over the counter and do not require a prescription from a healthcare provider. This leaves an option for affected individuals to receive treatment and relief without a visit to the doctor. This is an important consideration given that 8% of women in California do not have access to health insurance and would not be prescribed alternative treatment options.[12]
This legislation reaches beyond California, as many retailers may not sell state-specific products. BAS products may leave shelves across the nation if prohibited in California. If these products are unavailable to current consumers, there is also the potential for affected individuals to seek boric acid intended for other applications to make homemade suppositories, which could put these individuals at a higher risk. Some research has claimed that BAS could be a safe, alternative, and economic option for women with recurrent and chronic symptoms of vaginitis when conventional treatment fails with atypical, resistant strains of fungi.2,[13]
However, given that there are concerns surrounding the hazardous nature of boric acid, insufficient data on safety, and that it is listed as a reproductive toxicant on the EU's List of Substances Prohibited in Cosmetic Products and the Candidate Chemical list for DTSC, more transparency could protect consumers and allow them to make an informed choice regarding the substances they introduce into their bodies. The author may wish to consider adding labeling requirements to any vaginal or vulvar products containing boric acid, including a clear warning that the product contains reproductively toxic chemicals. - Drugs or cosmetics, boric acid still burns. Though BAS are accessible and allow affected individuals the option for quick and affordable relief from vaginal infections, they have not undergone the rigorous testing and approval of the FDA. Arguments have been made that the products should forgo the approval process because they can be classified as cosmetics. However, changing how these products are marketed doesn’t change their contents or the ailments they are recommended to address. BAS capsules still contain a reproductively hazardous toxicant, one that has been regulated for cosmetics in the EU and will be regulated in California through statute. So regardless of whether BAS is classified as a drug or a cosmetic, the capsules need to be regulated, given the questionable safety of its contents, the ailments it treats, and the method in which it is introduced to the human body. It is laudable that the author proposes any exceptions that involve vaginal products containing the intentionally added ingredients to be regulated as a drug by the FDA or undergo safety trials, however, these products will be left on the market unregulated and without a warning label while they are undergoing clinical trials or pending a new drug application.
- When helping hurts: hazard vs. risk. The controversy surrounding BAS highlights the shortcomings in our approach to not only define potentially hazardous products in statute but also in considering hazards and risks. The prohibited chemicals in the EU Directive are evaluated based on hazard, or the potential to cause harm, whereas the U.S. evaluates chemicals on risk, or the likelihood to cause harm. This results in outright bans in the EU as opposed to safety assessments and concentration limits in the U.S.
AB 2762 (Muratsuchi, Chapter 314, Statutes of 2020) and AB 496 (Friedman, Chapter 441, Statutes of 2023) were efforts to align California's regulations with hazard-based assessments of the EU rather than risk-based assessments. Though this tends to be unfavorable with industries in California, prohibiting toxic chemicals has led to the development of alternative ingredients or the removal of toxic ingredients in the EU, and furthermore the increase in access to safer products. Because there are existing safer alternatives to BAS, a ban on boric acid may not limit options to improve vaginal health. If boric acid were banned in vaginal products, manufacturers may formulate other suppositories, which would hopefully have less associated risk, yet uncertain without further evaluation.
The question before the committee is to decide whether the risks associated with these products are worth the cost of potentially harming affected individuals. Due to the controversy surrounding boric acid, hazards associated with boric acid, guidance suggested by experts, and established statutes prohibiting boric acid, the uncodified declarations and findings are partial, uncomprehensive, and do not consider the nuance in the use of BAS. The committee may wish to reevaluate the accuracy of these claims and consider removing or amending all subdivisions of the declarations and findings.
- Opening the door for more exclusions? In response to AB 496 (Friedman, Chapter 441, Statutes of 2023), the Fragrance Creators Association advocated to exempt Lily aldehyde from the legislation due to safety standards established within the industry and the lack of risk. This was one example in which industry argued to maintain the status quo at the stake of public health. It is worth considering whether the current bill proposal could contribute to a history of industry attempting to exempt their products from regulation, though the products may still present a risk to public health. The move to make an exemption should not be made lightly as this may present an opportunity for other exemptions to be made for both chemicals and products. However, the author's intent to require these products to undergo regulatory processes is a productive outcome, and if other exemptions are to be made down the line, perhaps those products ought to follow a similar path.
- Beyond BAS. The proposed legislation declares that the prohibition of boric acid should not apply to a “vaginal or vulvar product” if it meets specified conditions of undergoing FDA approval or passes third-party placebo-controlled double-blind safety trials. This encompasses products beyond BAS, including douches, washes, and odor products, which are considered cosmetics. The provision to require products to pass third-party placebo-controlled double-blind safety trials creates a pathway for these products to be regulated and exempted from the ban. There has also been controversy surrounding these products and requests from health and advocacy organizations to remove boric acid from these products, so perhaps it is appropriate to prohibit all vaginal and vulvar products unless they display warning labeling and undergo safety trials, especially since there are safer alternatives to addressing vaginal odor.
Related/Prior Legislation
AB 496 (Friedman, Chapter 441, Statutes of 2023) prohibits, beginning January 1, 2027, the manufacture, sale, delivery, holding, or offering for sale in commerce of any cosmetic product containing 41 specified intentionally added ingredients.
AB 2771 (Friedman, Chapter 804, Statutes of 2022) prohibits any person or entity from manufacturing, selling, delivering, holding, or offering for sale in commerce any cosmetic product that contains any per- or polyfluoroalkyl substance (PFAS).
AB 2762 (Muratsuchi, Chapter 314, Statutes of 2020) prohibits, beginning January 1, 2025, the manufacture, sale, delivery, holding, or offering for sale in commerce of any cosmetic product containing 24 specified intentionally added ingredients.
SOURCE:
pH-D Feminine Health, LLC
SUPPORT:
American Congress of Obstetricians & Gynecologists - District Ix
Nutrablast
Ph-d Feminine Health, LLC
The Flex Company
1 Individual
OPPOSITION:
None Received
-- END --
Prutting, S. M., & Cerveny, J. D. (1998). Boric acid vaginal suppositories: a brief review. Infectious diseases in obstetrics and gynecology, 6(4), 191. ↑
Iavazzo, C., Gkegkes, I. D., Zarkada, I. M., & Falagas, M. E. (2011). Boric acid for recurrent vulvovaginal candidiasis: the clinical evidence. Journal of women's health, 20(8), 1245-1255. ↑
Paavonen, J. A., & Brunham, R. C. (2020). Vaginitis in nonpregnant patients: ACOG practice bulletin number 215. Obstetrics & Gynecology, 135(5), 1229-1230. ↑
Centers for Disease Control and Prevention. (2021). Vulvovaginal Candidiasis. www.cdc.gov/std/treatment-guidelines/candidiasis.htm#print ↑
Writer, C. I. R. (2024). Safety Assessment of Boric Acid and Sodium Borate as Used in Cosmetics. ↑
Chapin, R. E., & Ku, W. W. (1994). The reproductive toxicity of boric acid. Environmental health perspectives, 102(suppl 7), 87-91. ↑
Farfán-García, E. D., Castillo-Mendieta, N. T., Ciprés-Flores, F. J., Padilla-Martínez, I. I., Trujillo-Ferrara, J. G., & Soriano-Ursúa, M. A. (2016). Current data regarding the structure-toxicity relationship of boron-containing compounds. Toxicology letters, 258, 115-125. ↑
Sevim, Ç., & Kara, M. (2022). Boron and boron-containing compounds toxicity. In The Toxicity of Environmental Pollutants. IntechOpen. ↑
Donders, G., Sziller, I. O., Paavonen, J., Hay, P., de Seta, F., Bohbot, J. M., ... & Mendling, W. (2022). Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion. Frontiers in Cellular and Infection Microbiology, 12, 934353. ↑
Farr, A., Effendy, I., Frey Tirri, B., Hof, H., Mayser, P., Petricevic, L., ... & Mendling, W. (2021). Guideline: vulvovaginal candidosis (AWMF 015/072, level S2k). Mycoses, 64(6), 583-602. ↑
Kirk-Othmer Encyclopedia of Chemical Technology. 3rd ed., Volumes 1-26. New York, NY: John Wiley and Sons, 1978-1984., p. V4: 76 (1978) ↑
KFF (2023). California Women’s Health Insurance Coverage Data ↑
Mittelstaedt, R., Kretz, A., Levine, M., Handa, V. L., Ghanem, K. G., Sobel, J. D., ... & Tuddenham, S. (2021). Data on safety of intravaginal boric acid use in pregnant and nonpregnant women: a narrative review. Sexually transmitted diseases, 48(12), e241-e247. ↑
Discussed in Hearing
View Older HearingsBill Author
Bill Co-Author(s):